var title_f9_60_10176="Laser induced purpura";
var content_f9_60_10176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Purpura due to a pulsed dye laser",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Temporary purpura can occur during treatment with pulsed dye lasers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10176=[""].join("\n");
var outline_f9_60_10176=null;
var title_f9_60_10177="Six months after RF treatment";
var content_f9_60_10177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The \"Stretta\" procedure post treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram of the gastroesophageal junction at six months after the procedure illustrating lesion resorption and collagen contraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George Triadafilopoulos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10177=[""].join("\n");
var outline_f9_60_10177=null;
var title_f9_60_10178="Fixed drug eruption before after";
var content_f9_60_10178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption (FDE): Lesion reactivation upon challenge with the causative drug",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical resting hyperpigmented FDE lesions before and after clinical challenge with the causative drug: erythematous macules develop only in the pigmented lesions. The surrounding skin is unaffected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17:201. Copyright &copy; 2007 John Libbey Eurotext. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10178=[""].join("\n");
var outline_f9_60_10178=null;
var title_f9_60_10179="Erythema multiforme-like FDE";
var content_f9_60_10179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption resembling erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A case of fixed drug eruption misdiagnosed as herpes-associated erythema multiforme. The lesions were reproduced by the administration of the suspected drug.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10179=[""].join("\n");
var outline_f9_60_10179=null;
var title_f9_60_10180="Difluprednate: Patient drug information";
var content_f9_60_10180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Difluprednate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/16/20739?source=see_link\">",
"     see \"Difluprednate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6741203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Durezol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3828342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701948",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to difluprednate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703156",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an eye infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 10 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12166 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5A1610FE52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10180=[""].join("\n");
var outline_f9_60_10180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6741203\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016638\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016637\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016642\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016643\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016645\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016640\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016641\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016646\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016647\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/16/20739?source=related_link\">",
"      Difluprednate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"UTD.htm?7/34/7713?source=related_link\">",
"      Difluprednate: International drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_60_10181="Endosc RFA HALO360";
var content_f9_60_10181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Endoscopic images of a primary circumferential ablation of Barrett's esophagus using the HALO360 system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     (A)",
"    </strong>",
"    Long-segment Barrett's esophagus with high-grade dysplasia.",
"    <br>",
"     <strong>",
"      (B)",
"     </strong>",
"     The HALO360+ catheter is introduced and inflated at the upper end of the Barrett's segment.",
"     <br>",
"      <strong>",
"       (C)",
"      </strong>",
"      The whitish coagulum resulting from ablation.",
"      <br>",
"       <strong>",
"        (D)",
"       </strong>",
"       After ablation of the whole Barrett's segment and cleaning of the electrode and ablation zone, the catheter is reintroduced for a second ablation pass.",
"       <br>",
"        <strong>",
"         (E)",
"        </strong>",
"        The second ablation pass results in a tan-colored ablation zone.",
"        <br>",
"         <strong>",
"          (F)",
"         </strong>",
"         Treatment effect after two circumferential ablation passes.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Reproduced with permission of www.endosurgery.eu. Copyright &copy; 2010 Esophageal Research Foundation Amsterdam.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10181=[""].join("\n");
var outline_f9_60_10181=null;
var title_f9_60_10182="Oligodendroglioma Light";
var content_f9_60_10182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oligodendroglioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of an oligodendroglioma. The tumor appears as a sheet of rounded cells with a well-defined cytoplasmic membrane and an empty-looking cytoplasm (fried egg appearance).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Smith, MD, University of Massachusetts.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10182=[""].join("\n");
var outline_f9_60_10182=null;
var title_f9_60_10183="Acyclovir: An overview";
var content_f9_60_10183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acyclovir: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/60/10183/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/60/10183/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/60/10183/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/60/10183/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/60/10183/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/60/10183/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/60/10183/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is widely used in the treatment of herpesvirus infections, particularly herpes simplex virus (HSV) and varicella-zoster virus (VZV). An overview of the mechanisms of action of and resistance to acyclovir and its major clinical uses will be provided here.",
"   </p>",
"   <p>",
"    Dosing and treatment of the specific clinical syndromes are described in greater detail on the appropriate topic reviews.",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , which are later generation agents with a similar mechanism of action, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30003?source=see_link\">",
"     \"Valacyclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6308?source=see_link\">",
"     \"Famciclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72507949\">",
"    <span class=\"h1\">",
"     ACYCLOVIR SHORTAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of November 2012, there is a shortage of intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the United States due to a manufacturing delay [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. IV acyclovir, if available, is the drug of choice for the following indications: neonates with proven herpes simplex virus (HSV) disease, pregnant women with HSV or varicella-zoster virus (VZV) infection, and individuals with herpes simplex encephalitis; during this shortage, IV acyclovir should be reserved for patients with these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    is an acyclic analog of the nucleoside guanosine that has established antiviral efficacy in the treatment of cytomegalovirus infections. Ganciclovir also inhibits the replication of other herpesviruses in vitro, including HSV-1 and HSV-2; however, there are few clinical data on the use of this antiviral medication for the clinical indications listed above.",
"   </p>",
"   <p>",
"    Pending resolution of the IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    shortage, guidance on the management and treatment of these various infections is listed below. Consultation with an infectious disease specialist is recommended. All dosing recommendations for the antiviral agents listed below are for patients with normal renal function; dosage adjustments are required for patients with renal insufficiency.",
"   </p>",
"   <p>",
"    Clinicians need to be aware that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is associated with more toxicity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , particularly bone marrow suppression (anemia, leukopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia). Hematologic monitoring is recommended in patients receiving ganciclovir. Ganciclovir should be used in pregnancy only if the potential benefit outweighs the potential risk to the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link\">",
"     \"Ganciclovir and valganciclovir: An overview\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    has been associated with decreased renal function and electrolyte abnormalities. Monitoring of renal function and electrolytes is recommended in patients taking foscarnet. In addition, patients should receive prehydration with normal saline before each dose of foscarnet. The concomitant administration of other nephrotoxic agents should be avoided, when possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link&amp;anchor=H6#H6\">",
"     \"Foscarnet: An overview\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another antiviral agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , does not cross the blood-brain barrier and should",
"    <strong>",
"     not",
"    </strong>",
"    be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in patients with central nervous system infections.",
"    <br/>",
"    <br/>",
"    Clinicians should check the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm\">",
"     US Food and Drug Administration's website",
"    </a>",
"    for information about the availability of IV acyclovir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72507972\">",
"    <span class=\"h2\">",
"     Herpes simplex encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspected or documented HSV encephalitis (if IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is unavailable), we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (for infants &le;90 days old: 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for infants &gt;90 days old, children, and adults: 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    ever 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/3\">",
"     3",
"    </a>",
"    ]. If ganciclovir cannot be given, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    (for infants and children: 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for adults: 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours or 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 hours). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link&amp;anchor=H19#H19\">",
"     \"Herpes simplex virus type 1 encephalitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72507979\">",
"    <span class=\"h2\">",
"     Neonatal herpes simplex infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspected neonatal HSV infection (if IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is unavailable), we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (for infants &le;90 days old: 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for infants &gt;90 days old: 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/3\">",
"     3",
"    </a>",
"    ]. If ganciclovir cannot be given, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours). The duration of treatment is the same as it would be for acyclovir.",
"   </p>",
"   <p>",
"    Patients should be monitored closely for response to therapy because there is a lack of clinical experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for the treatment of neonatal HSV; this includes repeat sampling of cerebrospinal fluid for HSV PCR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72507986\">",
"    <span class=\"h2\">",
"     Varicella pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with suspected or documented varicella pneumonia (if IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is unavailable), we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (for infants &lt;90 days old: 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for infants &gt;90 days old, children, and adults: 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/3\">",
"     3",
"    </a>",
"    ]. If ganciclovir cannot be given, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    (for infants and children: 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for adults: 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours or 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 hours).",
"    <br/>",
"    <br/>",
"    Adults who have improved on IV ganciclovir can be switched to a high dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (in adults: 2000 mg four times daily) provided that they are expected to absorb oral medications adequately. In adults who are not severely ill, it is reasonable to give a lower dose of valacyclovir (1000 mg three times daily). We do not recommend oral acyclovir in this situation since it is not highly bioavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72507993\">",
"    <span class=\"h2\">",
"     Disseminated herpes simplex virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV infection can cause disseminated disease in immunocompromised and immunocompetent hosts. If IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is unavailable, for infants or for immunocompromised",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severely ill children and adults, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (for infants &lt;90 days old: 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for infants &gt;90 days old, children, and adults: 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/3\">",
"     3",
"    </a>",
"    ]. If ganciclovir cannot be given, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    (for infants and children: 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for adults: 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours or 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 hours). Adults who are improving on IV therapy can be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (1000 mg orally three times daily).",
"    <br/>",
"   </p>",
"   <p>",
"    For immunocompetent children or adults who are not severely ill (eg, patients experiencing their initial HSV episode, who may have lesions distant from the site of inoculation), we suggest initial therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (for children: 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72508000\">",
"    <span class=\"h2\">",
"     Disseminated herpes zoster infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus infection can cause disseminated disease in immunocompromised and immunocompetent hosts. If IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is unavailable, for immunocompromised patients or severely ill patients, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (for infants &lt;90 days old: 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for infants &gt;90 days old, children, and adults: 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/3\">",
"     3",
"    </a>",
"    ]. If ganciclovir cannot be given, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    (for infants and children: 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours; for adults: 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours or 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 hours). Patients who are improving on IV therapy can be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (for children: 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily).",
"   </p>",
"   <p>",
"    <br/>",
"    For immunocompetent patients who are not severely ill, we suggest initial therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (for children: 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily).",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13970285\">",
"    <span class=\"h2\">",
"     Esophageal herpes simplex infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with HSV esophagitis who are unable to take medications orally due to odynophagia, if IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is unavailable, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours). If ganciclovir cannot be given, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 to 12 hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72508007\">",
"    <span class=\"h2\">",
"     Mucocutaneous herpes simplex infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompetent patients with mucocutaneous HSV infection can be treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72508014\">",
"    <span class=\"h2\">",
"     Prophylaxis against HSV or VZV infections in transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For prophylaxis against HSV or VZV infections in adult transplant recipients, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (1000 mg two times daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    (500 mg twice daily). For patients who cannot take oral agents, if IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is unavailable, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    (9-[2-hydroxymethyl]guanine) is a nucleoside analog that selectively inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and varicella-zoster virus (VZV). After intracellular uptake, it is converted to acyclovir monophosphate by virally-encoded thymidine kinase. This step does not occur to any significant degree in uninfected cells and thereby lends specificity to the drug's activity. The monophosphate derivative is subsequently converted to acyclovir triphosphate by cellular enzymes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    triphosphate competitively inhibits viral DNA polymerase by acting as an analog to deoxyguanosine triphosphate (dGTP). Incorporation of acyclovir triphosphate into DNA results in chain termination since the absence of a 3' hydroxyl group prevents the attachment of additional nucleosides. Acyclovir triphosphate has a much higher affinity for viral DNA polymerase than for the cellular homolog, yielding a high therapeutic ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spectrum of activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In descending order of susceptibility,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is active against HSV types 1 and 2 (HSV-1, HSV-2), VZV, and Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/4\">",
"     4",
"    </a>",
"    ]. Cytomegalovirus (CMV), which does not encode thymidine kinase, is resistant at clinically achievable levels. Activity versus human herpes viruses 6, 7 and 8 is not well defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three mechanisms have been shown to endow herpes simplex viruses with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , a phenomenon rare in the immunocompetent host [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced or absent thymidine kinase",
"     </li>",
"     <li>",
"      Altered thymidine kinase activity resulting in decreased",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      phosphorylation",
"     </li>",
"     <li>",
"      Altered viral DNA polymerase with decreased affinity for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      triphosphate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    , which is a prodrug of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , which is a prodrug of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    , have a similar mechanism of action as acyclovir. Thus, HSV isolates resistant to acyclovir are also resistant to valacyclovir, famciclovir, and penciclovir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link&amp;anchor=H46#H46\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Antiviral drug resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistant herpes simplex viruses have been isolated from a variety of immunocompromised patients, including bone marrow and solid organ transplant recipients and those with the acquired immunodeficiency syndrome (AIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/8\">",
"     8",
"    </a>",
"    ]. Analysis of isolates from a series of twelve AIDS patients with resistant HSV-2 indicated marked thymidine kinase deficiency in each case; these strains, not surprisingly, were cross-resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , which also requires phosphorylation for antiviral activity. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , a pyrophosphate analogue, is also a potent inhibitor of HSV DNA polymerase and does not require phosphorylation for its antiviral activity; in clinical trials, foscarnet has demonstrated efficacy in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"     \"Foscarnet: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VZV resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    has been reported in patients with AIDS. This rare problem usually occurs in the setting of chronic acyclovir therapy and has been linked to mutations in thymidine kinase, resulting in either deficient thymidine kinase or an enzyme with altered substrate specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BASIC PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    has modest oral bioavailability, about 15 to 30 percent, which decreases with higher doses. As an example, multiple oral doses of 200 to 800 mg yield steady-state peak plasma concentrations of 0.6 to 1.6",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    whereas intravenous dosing at 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours results in concentrations of 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Thus, the intravenous formulation should be used for serious infections such as disseminated varicella in an immunocompromised host. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\", section on 'Immunocompromised host'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is not highly bound to plasma protein (about 15 percent) and achieves widespread tissue and fluid penetration, including the cerebrospinal fluid, in which acyclovir concentrations are approximately 50 percent of those in plasma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link&amp;anchor=H19#H19\">",
"     \"Herpes simplex virus type 1 encephalitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excretion is predominantly renal, both by glomerular filtration and tubular secretion. The plasma half-life is two to three hours in patients with normal renal function; dosage modifications are required in the presence of renal insufficiency, which is a risk factor for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -related neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is remarkably well tolerated in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/14\">",
"     14",
"    </a>",
"    ]. There are, however, several important types of toxic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure, produced by the precipitation of relatively insoluble",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    crystals in the renal tubules, is an occasional complication of intravenous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The risk can be minimized by prior hydration (with the urine output maintained above 75",
"    <span class=\"nowrap\">",
"     mL/hour)",
"    </span>",
"    and slow drug infusion over one to two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurologic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare reports of neurologic toxicity, particularly in patients with underlying renal failure, have included agitation, tremors, delirium, hallucinations, and myoclonus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/17\">",
"     17",
"    </a>",
"    ]. Severe neurotoxicity, characterized by delirium and coma, has been described at doses as low as 800 mg twice daily in patients requiring dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/18\">",
"     18",
"    </a>",
"    ]. The potential for this complication is greater in patients treated with peritoneal dialysis, which is associated with minimal removal of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacokinetic studies suggest that daily doses of 600 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should lead to safe serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    concentrations in patients treated with peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/19\">",
"     19",
"    </a>",
"    ]. For hemodialysis, a loading dose of 400 mg followed by maintenance dosing of 200 mg twice daily plus 400 mg after each dialysis is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients who develop serious neurotoxicity should be treated with hemodialysis to remove the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     USE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    has been assigned to the US Food and Drug Administration (FDA) Pregnancy Category B in which there is no clear evidence of risk in humans. Although controlled studies have not been performed, several large observational studies have shown reassuring data regarding the safety of acyclovir during pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational cohort of nearly 838,000 live-born infants in Denmark from 1996 to 2008, 1804 pregnancies had been exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      during the first trimester of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/21\">",
"       21",
"      </a>",
"      ]. However, exposure to antiviral therapy was not associated with an increased risk of a birth defect.",
"     </li>",
"     <li>",
"      Analysis of 1129 pregnancies exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , 712 during the first trimester, from 1984 to 1997, failed to reveal an increase in birth defects when compared with the rate expected in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?9/60/10183/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     USE OF ACYCLOVIR IN IMMUNOCOMPETENT PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is used for the treatment of herpes simplex virus, herpes zoster, and primary varicella infection in immunocompetent and immunocompromised hosts. It is also occasionally used for postexposure prophylaxis after exposure to varicella. Further information can be found in the appropriate topic selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28068474\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      is widely used in the treatment of herpesvirus infections, particularly herpes simplex virus (HSV) and varicella-zoster virus (VZV). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As of November 2012, there is a shortage of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      in the United States. Treatment recommendations for the use of alternative antiviral agents for various clinical manifestations are presented above. (See",
"      <a class=\"local\" href=\"#H72507949\">",
"       'Acyclovir shortage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After intracellular uptake,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      is converted to acyclovir monophosphate by virally-encoded thymidine kinase; this step does not occur to any significant degree in uninfected cells and thereby lends specificity to the drug's activity. The monophosphate derivative is subsequently converted to acyclovir triphosphate, which leads to DNA chain termination. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      -resistant herpes simplex viruses have been isolated from a variety of immunocompromised patients, including bone marrow and solid organ transplant recipients and those with the acquired immunodeficiency syndrome (AIDS). However, acyclovir-resistant herpes viruses are rarely detected in the immunocompetent host. Clinicians need to be aware that herpes simplex viral isolates that are resistant to acyclovir are also resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       Foscarnet",
"      </a>",
"      can be effective in this clinical scenario. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The oral formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      has modest oral bioavailability; thus, the intravenous formulation should be used for serious infections, such as disseminated varicella in an immunocompromised host. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Basic pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      is generally well tolerated. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although no controlled studies among pregnant women have been performed, large observational studies have suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      use during the first trimester of pregnancy is not associated with an increased risk of teratogenicity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Use in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. file://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Current Drug Shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online. Antiviral recommendations for herpes simplex virus (HSV) and varicella zoster virus (vzv) infections in hospitalized pediatric patients during the intravenous acyclovir shortage. file://aapredbook.aappublications.org/site/news/acyclovir.xhtml (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/4\">",
"      Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/5\">",
"      Hirsch MS, Swartz MN. Drug therapy: antiviral agents (second of two parts). N Engl J Med 1980; 302:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/6\">",
"      Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/7\">",
"      Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 Suppl 5:S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/8\">",
"      Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990; 112:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/9\">",
"      Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/10\">",
"      Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992; 92:30S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/11\">",
"      Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994; 170:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/12\">",
"      Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 1983; 8:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/13\">",
"      Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of the literature. South Med J 1994; 87:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/14\">",
"      Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/15\">",
"      Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988; 84:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/16\">",
"      Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/17\">",
"      Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis 1988; 157:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/18\">",
"      Davenport A, Goel S, Mackenzie JC. Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 20:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/19\">",
"      Stathoulopoulou F, Almond MK, Dhillon S, Raftery MJ. Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. Nephron 1996; 74:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/20\">",
"      Almond MK, Fan S, Dhillon S, et al. Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. Nephron 1995; 69:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10183/abstract/21\">",
"      Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304:859.",
"     </a>",
"    </li>",
"    <li>",
"     pregnancyregistry.gsk.com/acyclovir.html (Accessed on September 25, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8332 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10183=[""].join("\n");
var outline_f9_60_10183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28068474\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72507949\">",
"      ACYCLOVIR SHORTAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72507972\">",
"      Herpes simplex encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72507979\">",
"      Neonatal herpes simplex infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72507986\">",
"      Varicella pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72507993\">",
"      Disseminated herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72508000\">",
"      Disseminated herpes zoster infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13970285\">",
"      Esophageal herpes simplex infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72508007\">",
"      Mucocutaneous herpes simplex infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72508014\">",
"      Prophylaxis against HSV or VZV infections in transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spectrum of activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BASIC PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurologic toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      USE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      USE OF ACYCLOVIR IN IMMUNOCOMPETENT PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28068474\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8332\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8332|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6308?source=related_link\">",
"      Famciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=related_link\">",
"      Neonatal herpes simplex virus infection: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30003?source=related_link\">",
"      Valacyclovir: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_60_10184="Desmopressin: Drug information";
var content_f9_60_10184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Desmopressin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/13/31957?source=see_link\">",
"    see \"Desmopressin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"    see \"Desmopressin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DDAVP&reg;;",
"     </li>",
"     <li>",
"      Stimate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Desmopressin&reg;;",
"     </li>",
"     <li>",
"      DDAVP&reg;;",
"     </li>",
"     <li>",
"      DDAVP&reg; Melt;",
"     </li>",
"     <li>",
"      Minirin&reg;;",
"     </li>",
"     <li>",
"      Novo-Desmopressin;",
"     </li>",
"     <li>",
"      Octostim&reg;;",
"     </li>",
"     <li>",
"      PMS-Desmopressin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F157868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antihemophilic Agent;",
"     </li>",
"     <li>",
"      Hemostatic Agent;",
"     </li>",
"     <li>",
"      Vasopressin Analog, Synthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F157828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diabetes insipidus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., SubQ:",
"     </i>",
"     U.S. labeling: 2-4 mcg/day (0.5-1 mL) in 2 divided doses or one-tenth (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     ) of the maintenance intranasal dose. Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V., SubQ:",
"     </i>",
"     Canadian labeling (not in U.S. labeling): 1-4 mcg (0.25-1 mL) once daily or one-tenth (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     ) of the maintenance intranasal dose. Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal (100 mcg/mL nasal solution):",
"     </i>",
"     10-40 mcg/day (0.1-0.4 mL) divided 1-3 times/day; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover.",
"     <b>",
"      Note:",
"     </b>",
"     The nasal spray pump can only deliver doses of 10 mcg (0.1 mL) or multiples of 10 mcg (0.1 mL); if doses other than this are needed, the rhinal tube delivery system is preferred. Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     U.S. labeling: Initial: 0.05 mg twice daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.1-1.2 mg divided 2-3 times/day). Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling (not in U.S. labeling): Initial: 0.1 mg 3 times/day; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.3-1.2 mg divided 3 times/day). Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sublingual formulation:",
"     </i>",
"     Canadian labeling (not in U.S. labeling): Initial: 60 mcg 3 times/day; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis. Usual maintenance: 60-120 mcg 3 times/day (range: 120-720 mcg divided 2-3 times/day). Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nocturnal enuresis:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     0.2 mg at bedtime; dose may be titrated up to 0.6 mg to achieve desired response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hemophilia A and mild-to-moderate von Willebrand disease (type 1):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     0.3 mcg/kg by slow infusion; if used preoperatively, administer 30 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling (not in U.S. labeling): Maximum I.V. dose: 20 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal (using high concentration spray [1.5 mg/mL]):",
"     </i>",
"     &lt;50 kg: 150 mcg (1 spray); &gt;50 kg: 300 mcg (1 spray each nostril); repeat use is determined by the patient's clinical condition and laboratory work. If using preoperatively, administer 2 hours before surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uremic bleeding associated with acute or chronic renal failure (unlabeled use)",
"     </b>",
"     (Watson, 1984): I.V.: 0.4 mcg/kg over 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of surgical bleeding in patients with uremia (unlabeled use)",
"     </b>",
"     (Mannucci, 1983): I.V.: 0.3 mcg/kg over 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F157850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"      see \"Desmopressin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diabetes insipidus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V., SubQ:",
"     </i>",
"     Canadian labeling (not in U.S. labeling): Infants and Children &ge;3 months: 0.4 mcg (0.1 mL) once daily or one-tenth (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     ) of the maintenance intranasal dose. Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., SubQ:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;12 years: No definitive dosing available.  Adult dosing should",
"     <b>",
"      not",
"     </b>",
"     be used in this age group; adverse events such as hyponatremia-induced seizures may occur. Dose should be reduced. Some have suggested an initial dosage range of 0.1-1 mcg in 1 or 2 divided doses (Cheetham, 2002). Initiate at low dose and increase as necessary. Closely monitor serum sodium levels and urine output; fluid restriction is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal (using 100 mcg/mL nasal solution):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children 3 months to 12 years: Initial: 5 mcg/day (0.05 mL/day) divided 1-2 times/day; range: 5-30 mcg/day (0.05-0.3 mL/day) divided 1-2 times/day; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover.",
"     <b>",
"      Note:",
"     </b>",
"     The nasal spray pump can only deliver doses of 10 mcg (0.1 mL) or multiples of 10 mcg (0.1 mL); if doses other than this are needed, the rhinal tube delivery system is preferred. Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     U.S. labeling: Children &ge;4 years: Initial: 0.05 mg twice daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.1-1.2 mg divided 2-3 times/day). Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling (not in U.S. labeling): Children &ge;5 years: Initial: 0.1 mg 3 times/day; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.3-1.2 mg divided 3 times/day). Divide daily doses so that the evening dose is 2 times higher than the morning or afternoon dose to ensure adequate antidiuresis during the night. Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sublingual formulation:",
"     </i>",
"     Canadian labeling (not in U.S. labeling): Infants and Children &ge;3 months: Initial: 60 mcg 3 times/day; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis. Usual maintenance: 60-120 mcg 3 times/day (range: 120-720 mcg divided 2-3 times/day); divide daily doses so that the evening dose is 2 times higher than the morning or afternoon dose to ensure adequate antidiuresis during the night. Fluid restriction should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hemophilia A and von Willebrand disease (type 1):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Infants and Children &ge;3 months: 0.3 mcg/kg by slow infusion; may repeat dose if needed; if used preoperatively, administer 30 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling (not in U.S. labeling): Maximum I.V. dose: 20 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse events such as hyponatremia-induced seizures have been reported especially in young children using this dosing regimen (Das, 2005; Molnar, 2005; Smith, 1989; Thumfart, 2005; Weinstein, 1989). Fluid restriction and careful monitoring of serum sodium levels and urine output are necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal (using high concentration spray [1.5 mg/mL]):",
"     </i>",
"     Infants and Children &ge;11 months: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nocturnal enuresis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;6 years: 0.2 mg at bedtime. Dose may be titrated up to 0.6 mg to achieve desired response. Fluid intake should be limited 1 hour prior to dose until the next morning, or at least 8 hours after administration.",
"     <b>",
"      Note:",
"     </b>",
"     In the Canadian labeling, use is approved for patients &ge;5 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sublingual:",
"     </i>",
"     Canadian labeling (not in U.S. labeling): Children &ge;5 years: Initial: 120 mcg at bedtime; dose may be titrated up to 360 mcg to achieve desired response. Fluid intake should be limited 1 hour prior to dose until the next morning, or at least 8 hours after administration.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F157829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2697324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use is contraindicated according to the manufacturer; however, has been used in acute and chronic renal failure patients experiencing uremic bleeding or for prevention of surgical bleeding (unlabeled uses) (Mannucci, 1983; Watson, 1984).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as acetate: 4 mcg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDAVP&reg;: 4 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDAVP&reg;: 4 mcg/mL (10 mL) [contains chlorobutanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as acetate: 0.1 mg/mL (2.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDAVP&reg;: 0.1 mg/mL (2.5 mL) [contains chlorobutanol; with rhinal tube]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as acetate [spray]: 0.1 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDAVP&reg;: 0.1 mg/mL (5 mL) [contains benzalkonium chloride; delivers 10 mcg/spray]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stimate&reg;: 1.5 mg/mL (2.5 mL) [contains benzalkonium chloride; delivers 150 mcg/spray]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate: 0.1 mg, 0.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDAVP&reg;: 0.1 mg, 0.2 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F6705371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, as acetate, sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DDAVP&reg; Melt: 60 mcg, 120 mcg, 240 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F157807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V. push, SubQ injection: Central diabetes insipidus: Withdraw dose from ampul into appropriate syringe size (eg, insulin syringe). Further dilution is not required. Administer as direct injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemophilia A, von Willebrand disease (type 1), and prevention of surgical bleeding in patients with uremia (unlabeled) (Mannucci, 1983): Infuse over 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute uremic bleeding (unlabeled) (Watson, 1984): May infuse over 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     DDAVP&reg;: Nasal pump spray: Delivers 0.1 mL (10 mcg); for doses &lt;10 mcg or for other doses which are not multiples, use rhinal tube. DDAVP&reg; Nasal spray delivers fifty 10 mcg doses. For 10 mcg dose, administer in one nostril. Any solution remaining after 50 doses should be discarded. Pump must be primed prior to first use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     DDAVP&reg; Rhinal tube: Insert top of dropper into tube (arrow marked end) in downward position. Squeeze dropper until solution reaches desired calibration mark. Disconnect dropper. Grasp the tube",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     inch from the end and insert tube into nostril until the fingertips reach the nostril. Place opposite end of tube into the mouth (holding breath). Tilt head back and blow with a strong, short puff into the nostril (for very young patients, an adult should blow solution into the child's nose). Reseal dropper after use.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F157875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F157806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Treatment of diabetes insipidus; maintenance of hemostasis and control of bleeding in hemophilia A with factor VIII coagulant activity levels &gt;5% and mild-to-moderate classic von Willebrand&rsquo;s disease (type 1) with factor VIII coagulant activity levels &gt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nasal solutions (DDAVP&reg; Nasal Spray and DDAVP&reg; Rhinal Tube): Treatment of central diabetes insipidus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nasal spray (Stimate&reg;): Maintenance of hemostasis and control of bleeding in hemophilia A with factor VIII coagulant activity levels &gt;5% and mild-to-moderate classic von Willebrand&rsquo;s disease (type 1) with factor VIII coagulant activity levels &gt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Treatment of central diabetes insipidus, temporary polyuria and polydipsia following pituitary surgery or head trauma, primary nocturnal enuresis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6158996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Uremic bleeding associated with acute or chronic renal failure; prevention of surgical bleeding in patients with uremia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F157866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency may not be defined (may be dose or route related).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased/decreased (I.V.), facial flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 5%), dizziness (intranasal; &le;3%), chills (intranasal; 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyponatremia, water intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (intranasal; 2%), gastrointestinal disorder (intranasal; &le;2%), nausea (intranasal; &le;2%), abdominal cramps, sore throat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transient increases in liver transaminases (associated primarily with tablets)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection: Burning pain, erythema, and swelling at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; Skeletal: Weakness (intranasal; &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis (intranasal; &le;2%), eye edema (intranasal; &le;2%), lacrimation disorder (intranasal; &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinitis (intranasal; 3% to 8%), epistaxis (intranasal; &le;3%), nostril pain (intranasal; &le;2%), cough, nasal congestion, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute cerebrovascular thrombosis (I.V.), acute MI (I.V.), agitation, allergic reactions (rare), anaphylaxis (rare), balanitis, chest pain, coma, diarrhea, dyspepsia, edema, insomnia, itching eyes, light-sensitive eyes, pain, palpitation, seizure, somnolence, tachycardia, thinking abnormal, vomiting, vulval pain, warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F157810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to desmopressin or any component of the formulation; hyponatremia or a history of hyponatremia; moderate-to-severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Type 2B or platelet-type (pseudo) von Willebrand&rsquo;s disease (injection, intranasal, oral, sublingual); known hyponatremia, habitual or psychogenic polydipsia, cardiac insufficiency or other conditions requiring diuretic therapy (intranasal, sublingual); nephrosis, severe hepatic dysfunction (sublingual); primary nocturnal enuresis (intranasal)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F157793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions (injectable and intranasal formulations): Severe reactions resembling hypersensitivity (eg, anaphylaxis) reactions have occurred rarely with I.V. and intranasal administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyponatremia: Use may rarely lead to hyponatremia and extreme decreases in plasma osmolality, resulting in seizures, coma, and death. Risk factors for hyponatremia with desmopressin use include cystic fibrosis, renal dysfunction, heart failure, young age, advanced age, inappropriate high fluid intake with desmopressin administration, a larger than recommended dose, and concomitant use of medications known to either increase thirst or cause syndrome of inappropriate ADH secretion (SIADH). Fluid restriction during use is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Acute cerebrovascular thrombosis and acute myocardial infarction have occurred (rare); use with caution in patients predisposed to thrombus formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery insufficiency or hypertensive cardiovascular disease; may increase or decrease blood pressure leading to changes in heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polydipsia (habitual or psychogenic): Use with caution in patients with habitual or psychogenic polydipsia. These patients are at greater risk of hyponatremia. Use in these patients is contraindicated in Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; von Willebrand&rsquo;s disease type 2B: Patients with type 2B von Willebrand&rsquo;s disease requiring hemostasis should not be treated with desmopressin since use may result in platelet aggregation, thrombocytopenia, and possibly thrombosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Fluid intake should be adjusted downward in the elderly to decrease the possibility of water intoxication and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Fluid intake should be adjusted downward in very young patients to decrease the possibility of water intoxication and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection and high concentration spray (1.5 mg/mL): Not for use in hemophilia B, type 2B von Willebrand disease, severe classic von Willebrand disease (type 1), or in patients with factor VIII antibodies.  In general, the injection and high concentration spray are also not recommended for use in patients with &le;5% factor VIII activity level, although it may be considered in selected patients with activity levels between 2% and 5%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intranasal: Consider alternative route of administration (I.V.) if changes in the nasal mucosa (scarring, edema) occur leading to unreliable absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tablet: Patients should be instructed to restrict fluid intake from 1 hour before to 8 hours after taking desmopressin tablets. Consider alternative route of administration (I.V. or intranasal) with inadequate therapeutic response at maximum recommended oral doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Appropriate use:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interruption of therapy: Therapy should be interrupted if the patient experiences an acute illness (eg, fever, recurrent vomiting or diarrhea), vigorous exercise, or any condition associated with an increase in water consumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term effects: Some patients may demonstrate a change in response after long-term therapy (&gt;6 months) characterized as decreased response or a shorter duration of response.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ChlorproMAZINE: May enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Demeclocycline: May diminish the therapeutic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May enhance the adverse/toxic effect of Desmopressin. LamoTRIgine may enhance the therapeutic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F157821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may decrease antidiuretic effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5559903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Anecdotal reports suggest congenital anomalies and low birth weight. However, causal relationship has not been established. Desmopressin has been used safely during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F157835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F157813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DDAVP Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mcg/mL (1 mL): $58.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DDAVP Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (5 mL): $341.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DDAVP Rhinal Tube Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (2.5 mL): $197.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Desmopressin Ace Spray Refrig Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (5 mL): $246.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Desmopressin Acetate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mcg/mL (1 mL): $7.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Desmopressin Acetate Spray Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (5 mL): $214.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Minirin Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/mL (5 mL): $153.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Stimate Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg/mL (2.5 mL): $682.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (DDAVP Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg (100): $601.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg (100): $866.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Desmopressin Acetate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg (100): $302.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg (100): $435.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F157802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure and pulse should be monitored during I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     For all indications, fluid intake, urine volume, and signs and symptoms of hyponatremia should be closely monitored especially in high-risk patient subgroups (eg, young children, elderly, patients with heart failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Diabetes insipidus: Urine specific gravity, plasma and urine osmolality, serum electrolytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemophilia A: Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII antigen levels, aPTT",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     von Willebrand disease: Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII von Willebrand antigen levels, bleeding time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nocturnal enuresis: Serum electrolytes if used for &gt;7 days",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F157814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adin Spray (IL);",
"     </li>",
"     <li>",
"      Adiuretin SD (HU);",
"     </li>",
"     <li>",
"      Adiuretin-SD (CZ, HN, PL);",
"     </li>",
"     <li>",
"      D-VOID (IN);",
"     </li>",
"     <li>",
"      DDAVP (BR, CN, IT, TW);",
"     </li>",
"     <li>",
"      DDAVP Desmopressin (PT);",
"     </li>",
"     <li>",
"      Defirin (GR);",
"     </li>",
"     <li>",
"      Desmin (KP);",
"     </li>",
"     <li>",
"      Desmomelt (GB, IE);",
"     </li>",
"     <li>",
"      Desmopresin DDAVP (AR);",
"     </li>",
"     <li>",
"      Desmospray (GB, IE);",
"     </li>",
"     <li>",
"      Desmotab (GB, IE);",
"     </li>",
"     <li>",
"      Minirin (AT, AU, BG, CH, CL, CO, DE, DK, EC, EE, FI, FR, HR, HU, IL, LU, MY, NO, NZ, PE, PH, PK, PY, RU, SE, TR, TW);",
"     </li>",
"     <li>",
"      Minirin DDAVP (AE, BH, CY, EG, GR, HK, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, TH, YE);",
"     </li>",
"     <li>",
"      Minirin Melt (AU, IL, TH);",
"     </li>",
"     <li>",
"      Minirin Nasal Spray (AU, NZ);",
"     </li>",
"     <li>",
"      Minirinmelt (FR);",
"     </li>",
"     <li>",
"      Minrin (BE, LU, NL);",
"     </li>",
"     <li>",
"      Minurin (ES);",
"     </li>",
"     <li>",
"      Nafiset (MX);",
"     </li>",
"     <li>",
"      Noctisson (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Octim (FR);",
"     </li>",
"     <li>",
"      Octim Nasal Spray (GB, IE);",
"     </li>",
"     <li>",
"      Octostim (AE, AR, AT, AU, BH, CH, CO, CY, EC, EG, ES, FI, HK, HU, IL, IQ, IR, JO, KW, LB, LY, MX, NL, NO, NZ, OM, QA, SA, SE, SG, SY, YE);",
"     </li>",
"     <li>",
"      Octostim Nasal Spray (KP);",
"     </li>",
"     <li>",
"      Octostin (AR);",
"     </li>",
"     <li>",
"      Pizzard (MX);",
"     </li>",
"     <li>",
"      Presinex (GB, IE, IL);",
"     </li>",
"     <li>",
"      Presinex Nasal Spray (SG);",
"     </li>",
"     <li>",
"      Uremin (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F157792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a dose dependent manner, desmopressin increases cyclic adenosine monophosphate (cAMP) in renal tubular cells which increases water permeability resulting in decreased urine volume and increased urine osmolality; increases plasma levels of von Willebrand factor, factor VIII, and t-PA contributing to a shortened activated partial thromboplastin time (aPTT) and bleeding time.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F157809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: Antidiuretic: 15-30 minutes; Increased factor VIII and von Willebrand factor (vWF) activity (dose related): 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak effect: Antidiuretic: 1 hour; Increased factor VIII and vWF activity: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion: Increased factor VIII and vWF activity: 30 minutes (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak effect: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral tablet: Antidiuretic: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak effect: 4-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Intranasal, I.V. infusion, Oral tablet: ~6-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Sublingual: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Intranasal: ~3.5%; Oral tablet: 5% compared to intranasal, 0.16% compared to I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Intranasal: ~3.5 hours; I.V. infusion: 3 hours; Oral tablet: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal impairment: &le;9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Asplund R and Aberg H, \"Desmopressin in Elderly Subjects With Increased Nocturnal Diuresis: A Two-Month Treatment Study,\"",
"      <i>",
"       Scand J Urol Nephrol",
"      </i>",
"      , 1993, 27(1):77-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/8493474/pubmed\" id=\"8493474\" target=\"_blank\">",
"        8493474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brewster UC and Hayslett JP, \"Diabetes Insipidus in the Third Trimester of Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(5 Pt 2):1173-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/15863571/pubmed\" id=\"15863571\" target=\"_blank\">",
"        15863571",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Byrnes JJ, Larcada A, and Moake JL, \"Thrombosis Following Desmopressin for Uremic Bleeding,\"",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 1988, 28(1):63-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/3259400/pubmed\" id=\"3259400\" target=\"_blank\">",
"        3259400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cattaneo M, \"Review of Clinical Experience of Desmopressin in Patients With Congenital and Acquired Bleeding Disorder,\"",
"      <i>",
"       Eur J Anesthesiol Suppl",
"      </i>",
"      , 1997, 14:10-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheetham T and Baylis PH, \"Diabetes Insipidus in Children,\"",
"      <i>",
"       Pediatr Drugs",
"      </i>",
"      , 2002, 4(12):785-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/12431131/pubmed\" id=\"12431131\" target=\"_blank\">",
"        12431131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chistolini A, Dragoni F, Ferrari A, et al, \"Intranasal DDAVP&reg;: Biological and Clinical Evaluation in Mild Factor VIII Deficiency,\"",
"      <i>",
"       Haemostasis",
"      </i>",
"      , 1991, 21(5):273-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/1806455/pubmed\" id=\"1806455\" target=\"_blank\">",
"        1806455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Couch P and Stumpf JL, \"Management of Uremic Bleeding,\"",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1990, 9(9):673-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/2171866/pubmed\" id=\"2171866\" target=\"_blank\">",
"        2171866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Das P, Carcao M, and Hitzler J, \"DDAVP-Induced Hyponatremia in Young Children,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2005, 27(6):330-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/15956888/pubmed\" id=\"15956888\" target=\"_blank\">",
"        15956888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Das P, Carcao M, and Hitzler J, \"Use of Recombinant Factor VIIa Prior to Lumbar Puncture in Pediatric Patients With Acute Leukemia,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2006, 47(2):206-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/16007583/pubmed\" id=\"16007583\" target=\"_blank\">",
"        16007583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dave SP, Greenstein AJ, Sachar DB, et al, \"Bleeding Diathesis in Amyloidosis With Renal Insufficiency Associated With Crohn's Disease: Response to Desmopressin,\"",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2002, 97(1):187-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/11808946/pubmed\" id=\"11808946\" target=\"_blank\">",
"        11808946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eller N, Kollenz CJ, and Hitzenberger G, \"A Comparative Study of Pharmacodynamics and Bioavailability of 2 Different Desmopressin Nasal Sprays,\"",
"      <i>",
"       Int J Clin Pharmacol Ther",
"      </i>",
"      , 1998, 36(3):139-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/9562229/pubmed\" id=\"9562229\" target=\"_blank\">",
"        9562229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eller N, Kollenz, Bauer P, et al, \"The Duration of Antidiuretic Response of Two Desmopressin Nasal Sprays,\"",
"      <i>",
"       Int J Clin Pharmacol Ther",
"      </i>",
"      , 1998, 36(9):494-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/9760011/pubmed\" id=\"9760011\" target=\"_blank\">",
"        9760011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lusher JM, \"Response to 1-Deamino-8-D-Arginine Vasopressin in von Willebrand Disease,\"",
"      <i>",
"       Haemostasis",
"      </i>",
"      , 1994, 24(5):276-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/7843638/pubmed\" id=\"7843638\" target=\"_blank\">",
"        7843638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mannucci PM and Cattaneo M, \"Desmopressin: A Nontransfusional Treatment of Hemophilia and von Willebrand Disease,\"",
"      <i>",
"       Haemostasis",
"      </i>",
"      , 1992, 22(5)276-80.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mannucci PM, Remuzzi G, Pusineri F, et al, \"Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in Uremia,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1983, 308(1):8-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/6401193/pubmed\" id=\"6401193\" target=\"_blank\">",
"        6401193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molnar Z, Farkas V, Nemes L, et al, \"Hyponatraemic Seizures Resulting From Inadequate Post-Operative Fluid Intake Following a Single Dose of Desmopressin,\"",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2005, 20(10):2265-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/16014348/pubmed\" id=\"16014348\" target=\"_blank\">",
"        16014348",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rembratt A, Graugaard-Jensen C, Senderovitz T, et al, \"Pharmacokinetics and Pharmacodynamics of Desmopressin Administered Orally Versus Intravenously at Daytime Versus Night-Time in Healthy Men Aged 55-70 Years,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 2004, 60(6):397-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/15197520/pubmed\" id=\"15197520\" target=\"_blank\">",
"        15197520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rembratt A, Riis A, and Norgaard JP, \"Desmopressin Treatment in Nocturia; An Analysis of Risk Factors for Hyponatremia,\"",
"      <i>",
"       Neurourol Urodyn",
"      </i>",
"      , 2005, 25(2):105-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/16304673/pubmed\" id=\"16304673\" target=\"_blank\">",
"        16304673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson DW and Robinson AG, \"Desmopressin,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1985, 103(2):228-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/3893256/pubmed\" id=\"3893256\" target=\"_blank\">",
"        3893256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robson WL, Leung AK, and Norgaard JP, \"The Comparative Safety of Oral Versus Intranasal Desmopressin for the Treatment of Children With Nocturnal Enuresis,\"",
"      <i>",
"       J Urol",
"      </i>",
"      , 2007, 178(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/17574054/pubmed\" id=\"17574054\" target=\"_blank\">",
"        17574054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith TJ, Gill JC, Ambruso DR, et al, \"Hyponatremia and Seizures in Young Children given DDAVP,\"",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 1989, 31(3):199-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/2500851/pubmed\" id=\"2500851\" target=\"_blank\">",
"        2500851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stenberg A and L&auml;ckgren G, \"Desmopressin Tablets in the Treatment of Severe Nocturnal Enuresis in Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 94(6 Pt 1):841-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/7970999/pubmed\" id=\"7970999\" target=\"_blank\">",
"        7970999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thumfart J, Roehr CC, Kapelari K, et al, \"Desmopressin Associated Symptomatic Hyponatremic Hypervolemia in Children. Are There Predictive Factors?\"",
"      <i>",
"       J Urol",
"      </i>",
"      , 2005, 174(1):294-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/15947670/pubmed\" id=\"15947670\" target=\"_blank\">",
"        15947670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watson AJ and Keogh JA., \"1-Deamino-8-D-Arginine Vasopressin as a Therapy for the Bleeding Diathesis of Renal Failure,\"",
"      <i>",
"       Am J Nephrol",
"      </i>",
"      , 1984, 4(1):49-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/6731500/pubmed\" id=\"6731500\" target=\"_blank\">",
"        6731500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watson AJ and Keogh JA, \"1-Deamino-8-d-Arginine Vasopressin (DDAVP): A Potential New Treatment for the Bleeding Diathesis of Acute Renal Failure,\"",
"      <i>",
"       Pharmatherapeutica",
"      </i>",
"      , 1984, 3(9):618-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/6728864/pubmed\" id=\"6728864\" target=\"_blank\">",
"        6728864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinstein RE, Bona RD, Altman AJ, et al, \"Severe Hyponatremia after Repeated Intravenous Administration of Desmopressin,\"",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 1989, 32(4):258-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/60/10184/abstract-text/2816922/pubmed\" id=\"2816922\" target=\"_blank\">",
"        2816922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9330 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10184=[""].join("\n");
var outline_f9_60_10184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157823\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157824\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157868\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157828\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157850\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157829\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2697324\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796022\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157804\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6705371\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157789\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157807\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157875\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157806\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6158996\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157866\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157810\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157793\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299137\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157798\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157821\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157800\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5559903\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157835\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157813\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157802\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157814\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157792\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157809\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/13/31957?source=related_link\">",
"      Desmopressin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=related_link\">",
"      Desmopressin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_60_10185="Coronal views of pharyngeal arch transformations";
var content_f9_60_10185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Coronal views of pharyngeal arch transformations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 654px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The first pouch hardly changes (A). It remains as a thin barrier between outside and inside - the tympanic membrane of the ear. On the inner side is the auditory tube, which is open to the throat, and on the outer side is the ear canal. The remaining clefts smooth over as a result of expansion and descent of the second arch, leaving the possibility of a trapped cyst or fistula in the connective tissue of the neck (B). The second pouch harbors a condensation of lymphatic tissue - the future tonsil (C). Parathyroid glands and critical immunologic tissue (the thymus gland) develop from involutions of the third and fourth pouches. From the midline of the ventral pharynx, the thyroid gland originates from the lining of the foramen cecum and descends external to the gut tube (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Sadler TW. Langman's Medical Embryology, 10th Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10185=[""].join("\n");
var outline_f9_60_10185=null;
var title_f9_60_10186="Neuronal control of the airways";
var content_f9_60_10186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuronal control of the airways",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/60/10186/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/60/10186/contributors\">",
"     Brendan J Canning, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/60/10186/contributors\">",
"     Beatrice Hoffmann, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/60/10186/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/60/10186/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/60/10186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/60/10186/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/60/10186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary function of the lungs is gas exchange. The upper and lower airways serve as a conduit for airflow to and from the gas exchange regions of the lungs. Nerves innervating the airway mucosa initiate homeostatic and defensive reflexes that preserve lung capacity for gas exchange. In airway diseases, such as allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD), homeostatic and defensive reflexes are dysfunctional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysregulated. Much of the pathology and many of the symptoms associated with upper and lower airway disease are directly or indirectly related to these changes in neuronal function (",
"    <a class=\"graphic graphic_figure graphicRef54768 \" href=\"UTD.htm?2/10/2222\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Neural control of the upper and lower airways will be reviewed here; other aspects of the pathogenesis of asthma, allergic rhinitis, and COPD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=see_link\">",
"     \"Pathogenesis of allergic rhinitis (rhinosinusitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Risk factors and risk reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UPPER AIRWAY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Afferent innervation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The olfactory nerve (cranial nerve I) provides afferent innervation associated with olfaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13801?source=see_link\">",
"     \"Anatomy and etiology of taste and smell disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remaining afferent innervation of the nasal mucosa arises from the trigeminal ganglion. These afferent nerve fibers branch extensively, innervating the epithelium, vessels and glands of the nasal mucosa. The extensive branching and innervation of multiple effectors in the mucosa, along with synthesis and peripheral transport of neuropeptides with many potential actions in the nose, provides the anatomical substrate necessary for producing axonal reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7079588\">",
"     'Axon reflexes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Reflexes can be initiated within the nose by a variety of stimuli including mechanical probing, hypertonic saline, cold",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dry air, histamine, allergen, nicotine, bradykinin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/2\">",
"     2",
"    </a>",
"    ]. Evidence for nasal afferent nerve subtypes that are differentially responsive to inflammatory mediators and irritants has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/3\">",
"     3",
"    </a>",
"    ]. While both histamine and bradykinin, when applied selectively to the nasal mucosa, initiate reflex-mediated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    -sensitive mucus secretion, only histamine readily initiates sneezing in normal patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The data are at least suggestive of the notion that nasal autonomic reflexes and sneezing are differentially regulated by nasal afferent nerve subtypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Efferent innervation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both sympathetic and parasympathetic nerves innervate the vasculature and glands of the nasal mucosa. Sympathetic branches of the upper four cervical nerves meet in the superior cervical ganglia; postganglionic sympathetic nerves travel to the nasal mucosa via branches of the facial nerve (cranial nerve VII). Parasympathetic branches of the trigeminal nerve (cranial nerve V) are relayed to the nasal mucosa via the sphenopalatine ganglion. Studies conducted in animals using selective stimulation of autonomic nerve pathways and pharmacological studies in human subjects indicate that sympathetic and parasympathetic nerves have opposing actions on their target tissues in the nasal mucosa (",
"    <a class=\"graphic graphic_table graphicRef55490 \" href=\"UTD.htm?11/9/11421\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52778 \" href=\"UTD.htm?7/20/7488\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Parasympathetic nerves and their neurotransmitters mediate mucus secretion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasodilatation. Conversely, sympathetic nerves and sympathetic neurotransmitters have little or no effect on mucus secretion, but constrict the blood vessels of the nasal mucosa and the capacitance vessels of the sinuses. The opposing actions of these systems likely determine levels of end organ function in the nose. Postganglionic nerves might also interact prejunctionally to modulate neurotransmitter release [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reflex regulation of upper airway function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nose filters and conditions inspired air. Reflexes initiated by activation of upper airway afferent nerves preserve and facilitate this conditioning function of the nose. Nasal reflexes also play an important defensive role for the exposed nasal mucosa, hindering infection and clearing inhaled pathogens and irritants either by sneezing or with mucus secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link&amp;anchor=H14#H14\">",
"     \"An overview of rhinitis\", section on 'Normal nasal reflexes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trigeminal afferent nerves terminate bilaterally and centrally in lateral regions of the pons, medulla and cervical spinal cord, either rostrally in the principal sensory nuclei of the trigeminal nerve, or caudally in the spinal trigeminal nuclei. The spinal trigeminal nuclei occupy extensive portions of the brainstem and cervical spinal cord and lie lateral but adjacent to many key structures in the brainstem relevant to the lower airways. The proximity of trigeminal afferent nerve terminations to brainstem structures involved in regulation of lower airway function and respiration may facilitate coordination of respiratory reflexes. This arrangement also provides the anatomical substrate for reflex effects on the lower airways initiated by upper airway irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LOWER AIRWAYS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extrinsic innervation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vagus nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lower airways and lungs are innervated bilaterally by the vagus nerves. The majority of vagal fibers projecting to the airways and lungs are afferent (or sensory) in nature [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Vagal afferent nerves have their cell bodies in one of two ganglia: The jugular (superior vagal) or nodose (inferior vagal) ganglia. The remaining vagal nerve fibers projecting to the airways are preganglionic parasympathetic nerve fibers innervating parasympathetic ganglia, and motor nerve fibers innervating the striated muscle of the larynx and upper airways (",
"    <a class=\"graphic graphic_figure graphicRef72678 \" href=\"UTD.htm?15/29/15824\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Vagal afferent nerve fibers terminate in integrative centers in the brainstem, primarily the nucleus tractus solitarius (nTS). The parasympathetic nerves and the laryngeal motor nerve fibers arise bilaterally from the dorsal motor nucleus of the vagus nerve (dmnX) and nucleus ambiguus (nA). Although these brainstem structures have a viscerotopic organization, considerable overlap among the sites of afferent nerve subtype termination and efferent projection is apparent. This overlap accounts in part for the clustering of autonomic reflexes (eg, effects on heart rate, respiratory pattern, airway caliber) initiated by selective activation of specific afferent nerve subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Spinal afferent and sympathetic nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postganglionic sympathetic nerves projecting to the airways arise bilaterally, primarily from the superior cervical ganglia and the thoracic sympathetic ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/13\">",
"     13",
"    </a>",
"    ]. Spinal afferent innervation has also been described and may regulate airway sympathetic nerve function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/14\">",
"     14",
"    </a>",
"    ]. The superior laryngeal nerves, recurrent laryngeal nerves, and the bronchial branches of the vagus nerves carry the vagal and spinal nerve fibers projecting to the airways. Both afferent and efferent vagal nerves project bilaterally, although ipsilateral innervation is far more extensive. There is no evidence for contralateral projections of postganglionic sympathetic nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intrinsic innervation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nerve plexuses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Afferent and efferent nerve fibers occupy multiple nerve plexuses in the airway wall from the larynx to the terminal bronchioles (",
"    <a class=\"graphic graphic_figure graphicRef55047 \" href=\"UTD.htm?9/5/9302\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67835 \" href=\"UTD.htm?43/18/44323\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Afferent nerve fibers surround epithelial cells in an epithelial nerve plexus. Efferent innervation of the epithelium has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Both afferent and efferent nerves are found in the plexus of the submucosa where most effectors of the airways (airway smooth muscle, mucus glands, arterioles) are located. Airway parasympathetic ganglia are primarily found in the extrapulmonary airways. Parasympathetic ganglia containing as few as one neuron to over 100 neurons are randomly and sparsely dispersed in the adventitial nerve plexus and are associated primarily with the extrapulmonary airways [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/19\">",
"     19",
"    </a>",
"    ]. The adventitial nerve plexus merges with the submucosal plexus in the intrapulmonary airways.",
"   </p>",
"   <p>",
"    With the exception of afferent nerve endings terminating in neuroepithelial bodies of the epithelium, airway afferent nerves form apparently nonspecialized (based on appearance) receptive fields in the epithelium and in and around various structures of the airway wall [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Swellings associated with airway afferent nerve terminals in the epithelium can contain synaptic vesicles with neurotransmitters that may be released during axonal reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/16\">",
"     16",
"    </a>",
"    ]. These nerve terminals are thought to be the peripheral terminations of airway and lung C-fibers. Afferent nerve fibers may also innervate other effector tissues in the airway wall, including glands, airway smooth muscle, blood vessels, and airway parasympathetic ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/19-27\">",
"     19-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postganglionic autonomic nerves innervate airway glands [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/22\">",
"     22",
"    </a>",
"    ], vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], and smooth muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26\">",
"     26",
"    </a>",
"    ]. Little discernible specialization is apparent prejunctionally on the postganglionic autonomic nerves of the airways or postjunctionally on effector cells innervated by these nerves. Although little change in nerve fiber densities in the smooth muscle from the trachea to the bronchioles is apparent, the neurochemistry of the nerve fibers may differ considerably in the large and small airways [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Airway parasympathetic ganglia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway ganglion neurons play important integrative roles in regulating airway autonomic tone. Synaptic integration is facilitated by the complex morphology of the ganglion neurons and by many biophysical properties that facilitate integration of synaptic input [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synaptic transmission between pre- and postganglionic parasympathetic nerves is mediated by acetylcholine acting on nicotinic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/19,30\">",
"     19,30",
"    </a>",
"    ]. Nicotinic receptor activation initiates depolarizations known as fast excitatory postsynaptic potentials (fEPSPs; (",
"    <a class=\"graphic graphic_figure graphicRef74594 \" href=\"UTD.htm?23/11/23728\">",
"     figure 5",
"    </a>",
"    )). Most fEPSPs are below the threshold required for action potential formation. Summation of multiple fEPSPs appears to be necessary to reach threshold for action potential generation. The capacity of airway ganglion neurons to filter preganglionic input can be modulated, either through the effects of noncholinergic neurotransmitters acting within the ganglia or by autacoid-dependent alterations in the excitability of the ganglia neurons.",
"   </p>",
"   <p>",
"    Airway ganglion neurons innervate adjacent neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/31\">",
"     31",
"    </a>",
"    ]. Collaterals of afferent nerves containing neuropeptides are also found in airway ganglia and regulate synaptic transmission in the ganglia through peripheral reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. Multiple neurotransmitters (eg, substance P, neurokinin A, nitric oxide, vasoactive intestinal peptide) in addition to acetylcholine have been localized to parasympathetic ganglion neurons innervating the lower airways (",
"    <a class=\"graphic graphic_picture graphicRef80605 \" href=\"UTD.htm?30/60/31682\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55490 \" href=\"UTD.htm?11/9/11421\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/9,26\">",
"     9,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reflex regulation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Afferent nerve subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway afferent nerves can be subclassified based on their neurochemistry, responsiveness to physical and chemical stimuli, myelination, conduction velocity, origin, and sites of termination in the airways and CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/8,20,32-36\">",
"     8,20,32-36",
"    </a>",
"    ]. Airway mechanoreceptors, of which there are at least three subtypes: the first and second subtypes respond to the dynamic (rapidly adapting receptors; RARs) and sustained (slowly adapting receptors; SARs) physical effects of lung inflation (",
"    <a class=\"graphic graphic_figure graphicRef51558 \" href=\"UTD.htm?16/60/17346\">",
"     figure 6",
"    </a>",
"    ). RARs can also be activated by bronchoconstrictors such as histamine, acetylcholine, and leukotrienes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/35\">",
"     35",
"    </a>",
"    ]. The third subtype of airway mechanoreceptor can be localized to the larynx, trachea, and mainstem bronchi and is activated by punctate mechanical stimuli and acid [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/37\">",
"     37",
"    </a>",
"    ]. These extrapulmonary vagal mechanoreceptors are differentiated from RARs and SARs by their insensitivity to changes in airway luminal pressures and airway smooth muscle contraction; they have been shown to play an essential role in the initiation of cough.",
"   </p>",
"   <p>",
"    When activated, airway mechanoreceptors initiate alterations in autonomic nerve activity and cough, and play an essential role in controlling respiratory rate and tidal volume. RARs and SARs are sporadically active during the respiratory cycle (",
"    <a class=\"graphic graphic_figure graphicRef51558 \" href=\"UTD.htm?16/60/17346\">",
"     figure 6",
"    </a>",
"    ). Their persistent activity may be of fundamental importance to the maintenance of baseline autonomic tone and respiratory pattern, and may influence evoked reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/34,35,38\">",
"     34,35,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Afferent nerves that are similar to somatic nociceptors also innervate the airways. Most airway nociceptors are unmyelinated C-fibers and are generally unresponsive to mechanical stimuli and are thus inactive during tidal breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/8,32,33,38\">",
"     8,32,33,38",
"    </a>",
"    ]. Airway nociceptors are, however, activated by inflammatory mediators such as bradykinin and 5-hydroxytryptamine (5-HT), but may also be activated by airway acidification, changes in airway surface liquid osmolarity, and by the vanilloid receptor agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef51558 \" href=\"UTD.htm?16/60/17346\">",
"     figure 6",
"    </a>",
"    ). Subtypes of bronchopulmonary C-fibers have been described and may play unique and possibly opposing roles in regulating airway and lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/8,39\">",
"     8,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    activates bronchopulmonary C-fibers by activating the transient receptor potential vanilloid type 1 (TRPV1). Endogenous ligands for TRPV1 include protons, 12- and 15-lipoxygenase products, N-arachidonoyl-dopamine and the endogenous cannabinoid receptor agonist anandamide [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/40-47\">",
"     40-47",
"    </a>",
"    ]. Airway C-fibers may also express the TRP channel transient receptor potential ankyrin type 1 (TRPA1). TRPA1 can be activated by a variety of endogenous (eg, prostaglandin A2) and exogenous irritants (eg, cinnamaldehyde, formaldehyde, toluene diisocyanate, bleach, ozone) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. When activated through TRPV1 or TRPA1 or by other cell surface receptors, bronchopulmonary C-fibers initiate autonomic nerve activity and cough, and have unique effects on respiratory pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of subacute and chronic cough in adults\", section on 'Etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Autonomic nerve subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathetic and parasympathetic nerves innervate the lower airways. Sympathetic nerves primarily innervate the bronchial vasculature, while airway parasympathetic nerves innervate the vasculature as well as airway smooth muscle and glands [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/22,24-28\">",
"     22,24-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Airway autonomic control was once thought of as a balance between the opposing actions of cholinergic-parasympathetic nerves and adrenergic-sympathetic nerves. Diseases such as asthma, it was inferred, were due to an imbalance of the actions of these autonomic neurotransmitters in the airways. Despite the accuracy of some aspects of this model and its utility in producing two of the major classes of drugs used in respiratory disease (anticholinergics and beta-agonists), it has become apparent that autonomic control is far more complex than previously envisioned [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/9,26\">",
"     9,26",
"    </a>",
"    ]. Multiple neurotransmitters have been localized to the autonomic nerves innervating the airways and their role as neurotransmitters",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuromodulators in the airways has been confirmed (",
"    <a class=\"graphic graphic_table graphicRef55490 \" href=\"UTD.htm?11/9/11421\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Autonomic reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postganglionic parasympathetic nerves innervate airway smooth muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26\">",
"     26",
"    </a>",
"    ], mucus glands [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/22\">",
"     22",
"    </a>",
"    ], and vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] throughout the airways. When activated, airway parasympathetic-cholinergic nerves initiate contractions of airway smooth muscle, mucus secretion, and vasodilatation.",
"   </p>",
"   <p>",
"    Although human airway smooth muscle expresses abundant beta adrenoceptors (primarily beta-2 adrenoceptors), functional evidence of sympathetic (adrenergic) innervation of human airway smooth muscle is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26\">",
"     26",
"    </a>",
"    ]. Catecholamines from the adrenal gland are likely the primary endogenous ligand for the beta adrenoceptors expressed on human airway smooth muscle. Sympathetic nerves also appear to play little or no role in regulating mucus secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/22\">",
"     22",
"    </a>",
"    ]. However, sympathetic nerves do innervate the airway vasculature, mediating vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Both sympathetic and parasympathetic nerves likely regulate mucociliary clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noncholinergic parasympathetic nerves are the only functional relaxant nerves innervating human airway smooth muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ]. The neurotransmitters mediating these relaxations remain poorly defined, but may include the peptides vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), and peptide histidine methionine (PHM). In addition, the gaseous transmitter nitric oxide (NO), synthesized from arginine by the neuronal isoform of NO synthase, may also play a role. These nonadrenergic, noncholinergic relaxant responses can be evoked in airways from the trachea to the small bronchi.",
"   </p>",
"   <p>",
"    Noncholinergic-parasympathetic nerves also regulate mucus secretion and vasodilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Simultaneous activation of cholinergic and noncholinergic parasympathetic nerves may have synergistic effects on airway mucus secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/52\">",
"     52",
"    </a>",
"    ]. As an example, vasoactive intestinal polypeptide and cholinergic stimulation synergistically increase mucous secretion.",
"   </p>",
"   <p>",
"    Studies in animals provide conclusive evidence that noncholinergic parasympathetic relaxant neurotransmitters are not co-released with acetylcholine from postganglionic parasympathetic nerves innervating airway smooth muscle. Rather, a distinct parasympathetic pathway mediates noncholinergic relaxations of airway smooth muscle. Reflexes also differentially regulate cholinergic and noncholinergic parasympathetic responses. Circumstantial evidence indicates a similar arrangement of the parasympathetic innervation of human airways [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,29,53-55\">",
"     26,29,53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many stimuli initiate reflex alterations in airway parasympathetic-cholinergic nerve activity. Bronchoconstrictors such as histamine, prostaglandin D2, leukotrienes, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , for example, initiate reflex bronchoconstriction, mucus secretion and vasodilatation. Nociceptor stimulants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , bradykinin, hypertonic saline, and acidic solutions initiate these reflexes and also cough. Other stimuli initiating reflex bronchospasm include chemoreceptor stimulation, esophageal afferent nerve stimulation, and upper airway afferent nerve stimulation. Chemoreceptor stimulation also evokes reflex dilatation of the bronchial vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/22,24,26,38,55-60\">",
"     22,24,26,38,55-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimuli initiating reflex bronchodilatation through activation of noncholinergic parasympathetic nerves include stimulants of airway mechanoreceptors and airway nociceptors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,55,61\">",
"     26,55,61",
"    </a>",
"    ]. In contrast, chemoreceptor stimulation is without apparent effect on noncholinergic-parasympathetic nerve activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/55\">",
"     55",
"    </a>",
"    ]. Activation of skeletal muscle afferent nerves as might happen during exercise also initiates reflex bronchodilatation, but primarily through",
"    <strong>",
"     withdrawal",
"    </strong>",
"    of baseline cholinergic tone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,62\">",
"     26,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not readily apparent what, if any, significance there is to the differential reflex regulation of airway cholinergic and noncholinergic parasympathetic nerves. Cholinergic reflexes are fast in onset and rapidly reversed whereas noncholinergic parasympathetic nerve-mediated responses are slow in onset, long lasting, and recover slowly, likely due to the slow inactivation of the noncholinergic neurotransmitters or the slow reversal of the intracellular events evoked by the relaxant agonists.",
"   </p>",
"   <p>",
"    The kinetics of cholinergic nerve-mediated responses renders these nerves ideally suited to regulate airway tone on a breath-to-breath basis. Cholinergic nerves can also be rapidly recruited during cough, thereby facilitating clearance of inhaled irritants, secretions, or pathogens by narrowing the airway passages and thus increasing airflow velocity. In contrast, the slow onset and resolution of the noncholinergic parasympathetic nerves make them unsuitable for vegetative reflexes, but may serve to normalize airway function following cough or reflex bronchospasm.",
"   </p>",
"   <p>",
"    Reflex regulation of airway sympathetic nerve activity is poorly described, and the role of adrenergic nerves and circulating catecholamines in regulating airways reactivity remains unclear. Beta adrenoceptor antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    have no effect on airways responsiveness in nonasthmatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,63-65\">",
"     26,63-65",
"    </a>",
"    ]. Adrenoreceptors and thus the endogenous catecholamines may, however, play an important role in regulating airway caliber and airway responsiveness in asthma. It seems likely that in humans, the catecholamines secreted by the adrenal glands are more important in regulating airway function than the sparse sympathetic-adrenergic innervation of the airways [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7079588\">",
"    <span class=\"h1\">",
"     AXON REFLEXES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory nerves innervating somatic tissues regulate local physiology and inflammation independent of the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. When activated, somatic nociceptive C-fibers release pro-inflammatory transmitters, such as substance P and possibly adenosine-5-triphosphate (ATP), to initiate neurogenic inflammation. This peripheral release of transmitters from sensory nerve collaterals and the resulting end organ effects are called the axon reflex. Afferent nerves innervating the airway mucosa of most species, including humans, express the anatomical attributes of the sensory nerves mediating axon reflexes in somatic tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/16,69,70\">",
"     16,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Airway afferent nerve endings may contain substance P, neurokinin A, and calcitonin gene-related peptide (CGRP). When administered exogenously, these putative neurotransmitters have profound effects in the airways, initiating bronchoconstriction, mucus secretion, vasodilation, plasma exudation, and inflammatory cell recruitment. These observations led to the intriguing hypothesis that axonal reflexes contribute to the pathogenesis of inflammatory airways disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/1,2,21,26\">",
"     1,2,21,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Axon reflexes have been described in the lower airways of rodents; however, the role of axon reflexes in the lower airways of humans is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26\">",
"     26",
"    </a>",
"    ]. Morphological studies of the human airway mucosa reveal a dense plexus of afferent nerves innervating the epithelium, but a general sparseness of neurokinin-containing nerve fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Axonal reflexes may, however, occur in the human nose.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    , hypertonic saline, or bradykinin challenge evokes mucus secretion, plasma extravasation, substance P release, and inflammatory cell recruitment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/1,2,5-7,70-76\">",
"     1,2,5-7,70-76",
"    </a>",
"    ]. The neurotransmitters mediating these effects have not been identified. Tachykinins do, however, initiate comparable effects when applied selectively to the human nasal mucosa, and substance P-containing nerve fibers innervate the human nasal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/1,2,70\">",
"     1,2,70",
"    </a>",
"    ]. Sensory innervation of the nasal mucosa is provided by an extensive network supplied by the trigeminal nerve. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Afferent innervation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chronic airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airways obstruction is attributable in part to dysregulation of airway autonomic nerves (",
"    <a class=\"graphic graphic_figure graphicRef54570 \" href=\"UTD.htm?29/34/30253\">",
"     figure 7",
"    </a>",
"    ). Elevated parasympathetic-cholinergic tone has been documented in both asthma and COPD, and anticholinergic medications reduce airways obstruction in rhinitis, asthma, and COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,77-81\">",
"     26,77-81",
"    </a>",
"    ]. Vasoconstriction initiated by alpha adrenoceptor agonists (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    ) reduces upper airways obstruction in patients with rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacological studies of nasal obstruction in human subjects indicate that sympathetic nerves tonically sustain upper airway patency through alpha1 adrenoceptor activation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/83\">",
"     83",
"    </a>",
"    ]. Histamine or the histamine H3 receptor agonist R-a-methyl-histamine, when applied exogenously to the human nasal mucosa, creates nasal blockage in part through histamine H3 receptor-dependent prejunctional inhibition of sympathetic-adrenergic nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/83\">",
"     83",
"    </a>",
"    ]. Whether or not sympathetic nerve-mediated regulation of vascular tone is altered in airways disease is unclear. It is also unclear what role nasal parasympathetic nerves play in regulating upper airway patency in normal human subjects, although their role in regulating mucus secretion and upper airways obstruction in rhinitis is well established.",
"   </p>",
"   <p>",
"    Several studies indicate that nitric oxide (NO)-dependent post-exercise hyperemia and plasma leakage in the lower airway mucosa may be a mechanism of cold air",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise-induced asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .) By contrast, it has been difficult to demonstrate any role for nasal nitric oxide in regulating upper airway patency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Airway hyperresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic allergic rhinitis have heightened responsiveness to stimuli that activate nasal mucosal afferent nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/5-7,73,74\">",
"     5-7,73,74",
"    </a>",
"    ]. These exaggerated responses are markedly reduced or abolished by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    pretreatment, confirming the reflexive nature of the responses. Allergic inflammation and asthma have also been associated with exaggerated sneezing and coughing reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/5-7,87,88\">",
"     5-7,87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with asthma are hyperresponsive to a wide variety of inhaled stimuli including histamine, bradykinin, prostanoids, cold air, nonisotonic solutions, adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    . This heightened reactivity is markedly reduced or abolished by anticholinergics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , suggesting that these stimuli cause an exaggerated parasympathetic nerve response (",
"    <a class=\"graphic graphic_table graphicRef53819 \" href=\"UTD.htm?1/21/1372\">",
"     table 2",
"    </a>",
"    ). Allergen challenge further increases airways reactivity through parasympathetic nerve recruitment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms for the heightened neuronal responsiveness associated with allergic inflammation are unknown. The enhanced coughing and sneezing reflexes associated with allergic airways disease would indicate that the afferent nerves become hyperexcitable during allergic inflammation. There may also be hyperinnervation of the airway mucosa in airways disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/89-93\">",
"     89-93",
"    </a>",
"    ]. Inflammation and disease may also initiate changes in neuronal function and pattern of innervation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/9,94,95\">",
"     9,94,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, autonomic nerves may become dysfunctional in airways disease. Allergic inflammation has been reported to alter function of prejunctional inhibitory muscarinic receptors on airway parasympathetic-cholinergic nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/96\">",
"     96",
"    </a>",
"    ]. Reactivity studies clearly implicate parasympathetic cholinergic nerves in airways hyperresponsiveness. A role for parasympathetic nerves in airways remodeling and inflammation has also been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/97-102\">",
"     97-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noncholinergic parasympathetic nerves may also become dysfunctional in airway disease. A failure of airways to dilate with deep inspiration may be a contributing mechanism of airways hyperresponsiveness in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/103\">",
"     103",
"    </a>",
"    ]. Noncholinergic parasympathetic nerves mediate bronchodilatation in part through nitric oxide (NO) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ]. Release of inhibitory NO during inhalational challenge may be attenuated in patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/104\">",
"     104",
"    </a>",
"    ]. Inhibiting NO synthesis prevents the bronchoprotective effects of deep inspiration and induces airways hyperresponsiveness to bradykinin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Moreover, mutation of the gene encoding the neuronal isoform of NO synthase is associated with a decreased concentration of exhaled nitric oxide, increased airways responsiveness, and an increased risk for developing asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergic inflammation may alter airway responses to noncholinergic parasympathetic nerve stimulation. Inhalation of allergen by a sensitizing individual reduces the ability of airway noncholinergic parasympathetic nerves and associated neurotransmitters to initiate bronchodilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchoprotection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/9,26\">",
"     9,26",
"    </a>",
"    ]. This may be due in part to an upregulation of arginase, which depletes the airways of the precursor for nitric oxide (arginine), or to an upregulation of glutathione-dependent formaldehyde dehydrogenase (also known as S-nitrosoglutathione (GSNO) reductase) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/109-112\">",
"     109-112",
"    </a>",
"    ]. GSNO reductase depletes the airways of the bronchodilator S-nitrosothiols, which form from precursors nitric oxide and thiol-containing compounds in the airways. Mast cell peptidases may also prevent relaxant responses evoked by the bronchodilating neurotransmitters vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP), and peptide histidine methionine (PHM) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/9,26\">",
"     9,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mediators of allergic inflammation such as histamine, prostaglandin D2, and the cysteinyl-leukotrienes are known to enhance neuronal excitability [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/2,8,9,19,113\">",
"     2,8,9,19,113",
"    </a>",
"    ]. Other mediators associated with allergic responses of the airways, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1b (IL-1b), chemokines, and eosinophil cationic proteins, are also known to activate or increase excitability of visceral sensory nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/2,114-117\">",
"     2,114-117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurotrophins may also contribute to allergen-induced neuronal hyperresponsiveness in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. Neurotrophins, such as nerve growth factor (NGF), are found in the airways and serum of allergic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/7,119-123\">",
"     7,119-123",
"    </a>",
"    ]. Allergen challenge induces neurotrophin release in the airways, and allergic asthmatics have high NGF levels in serum relative to atopic nonasthmatics. NGF induces hyperalgesia in somatic tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/124\">",
"     124",
"    </a>",
"    ]. Given acutely, NGF and brain derived neurotrophic factor (BDNF) induce airways hyperresponsiveness in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/125-128\">",
"     125-128",
"    </a>",
"    ]. In transgenic animals, NGF overexpression in the lung produces hyperinnervation and airways hyperresponsiveness in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/129\">",
"     129",
"    </a>",
"    ]. NGF also induces preprotachykinin gene expression in airway afferent nerves, mimicking exactly the effects of allergen on airway afferent nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/94,130,131\">",
"     94,130,131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential sources of neurotrophins include the airway epithelium, smooth muscle, T-cells, and mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/118,132-134\">",
"     118,132-134",
"    </a>",
"    ]. Other mediators associated with the airway mucosa that have neurotrophic effects include leukemia inhibitory factor (LIF), brain-derived and glial-derived neurotrophic factors (BDNF and GDNF), IL-6, IL-11, and endothelin-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough is one of the most common presenting symptoms of pulmonary disease. Cough reflexes play an essential role in the clearance of inhaled pathogens, aeroallergens, irritants, particulate matter, secretions, and aspirate and thus protect the airway mucosa from damage. Impaired",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insufficient cough reflexes markedly increase the risk for pulmonary infection. Cough therefore helps maintain airway function and lung capacity for gas exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/37,38,135\">",
"     37,38,135",
"    </a>",
"    ]. When poorly controlled, however, cough adversely impacts quality of life.",
"   </p>",
"   <p>",
"    The afferent nerves regulating cough include airway mechanoreceptors, which are activated by inhaled particulate and accumulated secretions, and airway C-fibers, which can be activated by bradykinin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , and a variety of other endogenous and exogenous irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/26,37,38\">",
"     26,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanoreceptors and C-fibers mediate similar reflex effects in the airways and it is not surprising that these afferent nerve subtypes might act synergistically to initiate reflexes. Such synergistic interactions are facilitated by the convergence of the central nerve terminals of these afferent nerves in key integrative sites in the brainstem such as the commissural nucleus of the solitary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. These interactions would be analogous to the processes initiating hyperalgesia and pain sensations in somatic tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/124\">",
"     124",
"    </a>",
"    ]. In the somatic nervous system, neurotransmitters released from the central nerve terminals of nociceptors facilitate synaptic neurotransmission at relay neurons of mechanoreceptors in a process known as central sensitization.",
"   </p>",
"   <p>",
"    Evidence for central sensitizing effects of airway nociceptors on cough and reflex bronchoconstriction, similar to the synergistic interactions in hyperalgesia, has been found in animal studies of the effect on cough reflexes of injecting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , substance P, and neurokinin antagonists into the nucleus solitarius [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. Interactions between afferent nerve subtypes at central integrative sites may explain how extrapulmonary disorders, such as gastroesophageal reflux disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/138,139\">",
"     138,139",
"    </a>",
"    ], allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/2\">",
"     2",
"    </a>",
"    ], and upper respiratory tract infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/60/10186/abstract/140,141\">",
"     140,141",
"    </a>",
"    ] influence pulmonary symptoms such as cough and reflex bronchospasm and perhaps airways hyperresponsiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7079462\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nerves innervating the airway mucosa initiate homeostatic and defensive reflexes that contribute to the regulation of airway caliber and mucous production and the initiation of reflexes, such as sneeze and cough.",
"     </li>",
"     <li>",
"      Both sympathetic and parasympathetic nerves innervate the vasculature and glands of the nasal mucosa (",
"      <a class=\"graphic graphic_figure graphicRef52778 \" href=\"UTD.htm?7/20/7488\">",
"       figure 2",
"      </a>",
"      ). Reflexes can be initiated within the nose by a variety of stimuli including mechanical probing, hypertonic saline, cold",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dry air, histamine, allergen, nicotine, bradykinin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In the lower airways, cholinergic-parasympathetic nerves mediate smooth muscle contraction, whereas adrenergic-sympathetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      noncholinergic parasympathetic nerves mediate smooth muscle relaxation (",
"      <a class=\"graphic graphic_figure graphicRef72678 \" href=\"UTD.htm?15/29/15824\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The cough reflex can be initiated by activation of airway mechanoreceptors (eg, by inhaled particulates and accumulated secretions) or airway C-fibers. Airway C fibers have chemoreceptors (eg, transient receptor potential vanilloid type 1, transient receptor potential ankyrin type 1) that can be activated by bradykinin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      , and a variety of other endogenous and exogenous irritants.",
"     </li>",
"     <li>",
"      In certain diseases of the airways, homeostatic and defensive reflexes in the airway mucosa become dysfunctional",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysregulated. As examples, elevated parasympathetic-cholinergic tone has been documented in both asthma and COPD, and allergic inflammation in allergic rhinitis and asthma is associated with exaggerated sneeze and cough reflexes.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/1\">",
"      Sarin S, Undem B, Sanico A, Togias A. The role of the nervous system in rhinitis. J Allergy Clin Immunol 2006; 118:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/2\">",
"      Canning BJ. Neurology of allergic inflammation and rhinitis. Curr Allergy Asthma Rep 2002; 2:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/3\">",
"      Taylor-Clark TE, Kollarik M, MacGlashan DW Jr, Undem BJ. Nasal sensory nerve populations responding to histamine and capsaicin. J Allergy Clin Immunol 2005; 116:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/4\">",
"      Baroody FM, Ford S, Lichtenstein LM, et al. Physiologic responses and histamine release after nasal antigen challenge. Effect of atropine. Am J Respir Crit Care Med 1994; 149:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/5\">",
"      Baraniuk JN, Silver PB, Kaliner MA, Barnes PJ. Perennial rhinitis subjects have altered vascular, glandular, and neural responses to bradykinin nasal provocation. Int Arch Allergy Immunol 1994; 103:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/6\">",
"      Riccio MM, Proud D. Evidence that enhanced nasal reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes. J Allergy Clin Immunol 1996; 97:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/7\">",
"      Sanico AM, Koliatsos VE, Stanisz AM, et al. Neural hyperresponsiveness and nerve growth factor in allergic rhinitis. Int Arch Allergy Immunol 1999; 118:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/8\">",
"      Coleridge JC, Coleridge HM. Afferent vagal C fibre innervation of the lungs and airways and its functional significance. Rev Physiol Biochem Pharmacol 1984; 99:1.",
"     </a>",
"    </li>",
"    <li>",
"     Undem BJ, Canning BJ. Neuronal control of airway function in allergy. In: Middleton's Allergy: Principles and Practice, 7th Ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, St Louis, MO 2009. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/10\">",
"      Mazzone SB, Canning BJ. Central nervous system control of the airways: pharmacological implications. Curr Opin Pharmacol 2002; 2:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/11\">",
"      Kubin L, Alheid GF, Zuperku EJ, McCrimmon DR. Central pathways of pulmonary and lower airway vagal afferents. J Appl Physiol 2006; 101:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/12\">",
"      Haxhiu MA, Kc P, Moore CT, et al. Brain stem excitatory and inhibitory signaling pathways regulating bronchoconstrictive responses. J Appl Physiol 2005; 98:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/13\">",
"      Kummer W, Fischer A, Kurkowski R, Heym C. The sensory and sympathetic innervation of guinea-pig lung and trachea as studied by retrograde neuronal tracing and double-labelling immunohistochemistry. Neuroscience 1992; 49:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/14\">",
"      Oh EJ, Mazzone SB, Canning BJ, Weinreich D. Reflex regulation of airway sympathetic nerves in guinea-pigs. J Physiol 2006; 573:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/15\">",
"      Sparrow MP, Weichselbaum M, McCray PB. Development of the innervation and airway smooth muscle in human fetal lung. Am J Respir Cell Mol Biol 1999; 20:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/16\">",
"      Lamb JP, Sparrow MP. Three-dimensional mapping of sensory innervation with substance p in porcine bronchial mucosa: comparison with human airways. Am J Respir Crit Care Med 2002; 166:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/17\">",
"      Dey RD, Satterfield B, Altemus JB. Innervation of tracheal epithelium and smooth muscle by neurons in airway ganglia. Anat Rec 1999; 254:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/18\">",
"      Adriaensen D, Brouns I, Van Genechten J, Timmermans JP. Functional morphology of pulmonary neuroepithelial bodies: extremely complex airway receptors. Anat Rec A Discov Mol Cell Evol Biol 2003; 270:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/19\">",
"      Myers AC. Transmission in autonomic ganglia. Respir Physiol 2001; 125:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/20\">",
"      Widdicombe J. Airway receptors. Respir Physiol 2001; 125:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/21\">",
"      Barnes PJ. Neurogenic inflammation in the airways. Respir Physiol 2001; 125:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/22\">",
"      Wine JJ. Parasympathetic control of airway submucosal glands: central reflexes and the airway intrinsic nervous system. Auton Neurosci 2007; 133:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/23\">",
"      Canning BJ, Reynolds SM, Anukwu LU, et al. Endogenous neurokinins facilitate synaptic transmission in guinea pig airway parasympathetic ganglia. Am J Physiol Regul Integr Comp Physiol 2002; 283:R320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/24\">",
"      Coleridge HM, Coleridge JC. Neural regulation of bronchial blood flow. Respir Physiol 1994; 98:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/25\">",
"      Haberberger R, Schemann M, Sann H, Kummer W. Innervation pattern of guinea pig pulmonary vasculature depends on vascular diameter. J Appl Physiol 1997; 82:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/26\">",
"      Canning BJ. Reflex regulation of airway smooth muscle tone. J Appl Physiol 2006; 101:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/27\">",
"      Myers AC, Goldie RG, Hay DW. A novel role for tachykinin neurokinin-3 receptors in regulation of human bronchial Ganglia neurons. Am J Respir Crit Care Med 2005; 171:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/28\">",
"      Ward JK, Barnes PJ, Springall DR, et al. Distribution of human i-NANC bronchodilator and nitric oxide-immunoreactive nerves. Am J Respir Cell Mol Biol 1995; 13:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/29\">",
"      Fischer A, Hoffmann B. Nitric oxide synthase in neurons and nerve fibers of lower airways and in vagal sensory ganglia of man. Correlation with neuropeptides. Am J Respir Crit Care Med 1996; 154:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/30\">",
"      Kajekar R, Rohde HK, Myers AC. The integrative membrane properties of human bronchial parasympathetic Ganglia neurons. Am J Respir Crit Care Med 2001; 164:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/31\">",
"      Zhu W, Dey RD. Projections and pathways of VIP- and nNOS-containing airway neurons in ferret trachea. Am J Respir Cell Mol Biol 2001; 24:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/32\">",
"      Ricco MM, Kummer W, Biglari B, et al. Interganglionic segregation of distinct vagal afferent fibre phenotypes in guinea-pig airways. J Physiol 1996; 496 ( Pt 2):521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/33\">",
"      Lee LY, Pisarri TE. Afferent properties and reflex functions of bronchopulmonary C-fibers. Respir Physiol 2001; 125:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/34\">",
"      Schelegle ES, Green JF. An overview of the anatomy and physiology of slowly adapting pulmonary stretch receptors. Respir Physiol 2001; 125:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/35\">",
"      Sant'Ambrogio G, Widdicombe J. Reflexes from airway rapidly adapting receptors. Respir Physiol 2001; 125:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/36\">",
"      Ho CY, Gu Q, Lin YS, Lee LY. Sensitivity of vagal afferent endings to chemical irritants in the rat lung. Respir Physiol 2001; 127:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/37\">",
"      Canning BJ, Mazzone SB, Meeker SN, et al. Identification of the tracheal and laryngeal afferent neurones mediating cough in anaesthetized guinea-pigs. J Physiol 2004; 557:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/38\">",
"      Canning BJ, Mori N, Mazzone SB. Vagal afferent nerves regulating the cough reflex. Respir Physiol Neurobiol 2006; 152:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/39\">",
"      Undem BJ, Chuaychoo B, Lee MG, et al. Subtypes of vagal afferent C-fibres in guinea-pig lungs. J Physiol 2004; 556:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/40\">",
"      Fox AJ, Urban L, Barnes PJ, Dray A. Effects of capsazepine against capsaicin- and proton-evoked excitation of single airway C-fibres and vagus nerve from the guinea-pig. Neuroscience 1995; 67:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/41\">",
"      Hwang SW, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 2000; 97:6155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/42\">",
"      Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/43\">",
"      Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002; 99:8400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/44\">",
"      Kollarik M, Undem BJ. Mechanisms of acid-induced activation of airway afferent nerve fibres in guinea-pig. J Physiol 2002; 543:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/45\">",
"      Shin J, Cho H, Hwang SW, et al. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci U S A 2002; 99:10150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/46\">",
"      Carr MJ, Kollarik M, Meeker SN, Undem BJ. A role for TRPV1 in bradykinin-induced excitation of vagal airway afferent nerve terminals. J Pharmacol Exp Ther 2003; 304:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/47\">",
"      Lin YS, Lee LY. Stimulation of pulmonary vagal C-fibres by anandamide in anaesthetized rats: role of vanilloid type 1 receptors. J Physiol 2002; 539:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/48\">",
"      Taylor-Clark TE, Nassenstein C, McAlexander MA, Undem BJ. TRPA1: a potential target for anti-tussive therapy. Pulm Pharmacol Ther 2009; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/49\">",
"      Birrell MA, Belvisi MG, Grace M, et al. TRPA1 agonists evoke coughing in guinea pig and human volunteers. Am J Respir Crit Care Med 2009; 180:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/50\">",
"      Materazzi S, Nassini R, Gatti R, et al. Cough sensors. II. Transient receptor potential membrane receptors on cough sensors. Handb Exp Pharmacol 2009; :49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/51\">",
"      Foster WM. Mucociliary transport and cough in humans. Pulm Pharmacol Ther 2002; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/52\">",
"      Choi JY, Joo NS, Krouse ME, et al. Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis. J Clin Invest 2007; 117:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/53\">",
"      Canning BJ, Undem BJ. Evidence that distinct neural pathways mediate parasympathetic contractions and relaxations of guinea-pig trachealis. J Physiol 1993; 471:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/54\">",
"      Dey RD, Altemus JB, Rodd A, et al. Neurochemical characterization of intrinsic neurons in ferret tracheal plexus. Am J Respir Cell Mol Biol 1996; 14:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/55\">",
"      Mazzone SB, Canning BJ. Evidence for differential reflex regulation of cholinergic and noncholinergic parasympathetic nerves innervating the airways. Am J Respir Crit Care Med 2002; 165:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/56\">",
"      Phipps RJ, Richardson PS. The effects of irritation at various levels of the airway upon tracheal mucus secretion in the cat. J Physiol 1976; 261:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/57\">",
"      Davis B, Roberts AM, Coleridge HM, Coleridge JC. Reflex tracheal gland secretion evoked by stimulation of bronchial C-fibers in dogs. J Appl Physiol 1982; 53:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/58\">",
"      Davis B, Chinn R, Gold J, et al. Hypoxemia reflexly increases secretion from tracheal submucosal glands in dogs. J Appl Physiol 1982; 52:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/59\">",
"      Alsberge M, Magno M, Lipschutz M. Carotid body control of bronchial circulation in sheep. J Appl Physiol 1988; 65:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/60\">",
"      Canning BJ, Reynolds SM, Mazzone SB. Multiple mechanisms of reflex bronchospasm in guinea pigs. J Appl Physiol 2001; 91:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/61\">",
"      Lammers JW, Barnes PJ, Chung KF. Nonadrenergic, noncholinergic airway inhibitory nerves. Eur Respir J 1992; 5:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/62\">",
"      Kaufman MP, Rybicki KJ. Muscular contraction reflexly relaxes tracheal smooth muscle in dogs. Respir Physiol 1984; 56:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/63\">",
"      Laitinen LA, Empey DW, Poppius H, et al. Effects of intravenous histamine on static lung compliance and airway resistance in normal man. Am Rev Respir Dis 1976; 114:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/64\">",
"      Allegra L, Bianco S. Non-specific broncho-reactivity obtained with an ultrasonic aerosol of distilled water. Eur J Respir Dis Suppl 1980; 106:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/65\">",
"      Schachter EN, Rimar S, Littner M, et al. Airway reactivity and exercise in healthy subjects. Chest 1982; 81:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/66\">",
"      Bruce, AN. Vasodilator axon reflexes. Q J Exp Physiol 1913; 6:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/67\">",
"      Lewis T. Nocifensor System of Nerves. Br Med J 1937; 1:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/68\">",
"      Jancs&oacute; N, Jancs&oacute;-G&aacute;bor A, Szolcs&aacute;nyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother 1967; 31:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/69\">",
"      Lundberg JM, H&ouml;kfelt T, Martling CR, et al. Substance P-immunoreactive sensory nerves in the lower respiratory tract of various mammals including man. Cell Tissue Res 1984; 235:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/70\">",
"      Stj&auml;rne P, Lundblad L, Angg&aring;rd A, et al. Tachykinins and calcitonin gene-related peptide: co-existence in sensory nerves of the nasal mucosa and effects on blood flow. Cell Tissue Res 1989; 256:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/71\">",
"      Mullol J, Raphael GD, Lundgren JD, et al. Comparison of human nasal mucosal secretion in vivo and in vitro. J Allergy Clin Immunol 1992; 89:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/72\">",
"      Sanico AM, Atsuta S, Proud D, Togias A. Dose-dependent effects of capsaicin nasal challenge: in vivo evidence of human airway neurogenic inflammation. J Allergy Clin Immunol 1997; 100:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/73\">",
"      Sanico AM, Atsuta S, Proud D, Togias A. Plasma extravasation through neuronal stimulation in human nasal mucosa in the setting of allergic rhinitis. J Appl Physiol 1998; 84:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/74\">",
"      Sanico AM, Philip G, Proud D, et al. Comparison of nasal mucosal responsiveness to neuronal stimulation in non-allergic and allergic rhinitis: effects of capsaicin nasal challenge. Clin Exp Allergy 1998; 28:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/75\">",
"      Stj&auml;rne P, Rinder J, Hed&eacute;n-Blomquist E, et al. Capsaicin desensitization of the nasal mucosa reduces symptoms upon allergen challenge in patients with allergic rhinitis. Acta Otolaryngol 1998; 118:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/76\">",
"      Baraniuk JN, Ali M, Yuta A, et al. Hypertonic saline nasal provocation stimulates nociceptive nerves, substance P release, and glandular mucous exocytosis in normal humans. Am J Respir Crit Care Med 1999; 160:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/77\">",
"      Kaiser HB, Findlay SR, Georgitis JW, et al. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. J Allergy Clin Immunol 1995; 95:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/78\">",
"      Bronsky EA, Druce H, Findlay SR, et al. A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. J Allergy Clin Immunol 1995; 95:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/79\">",
"      Maesen FP, Smeets JJ, Sledsens TJ, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995; 8:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/80\">",
"      O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/81\">",
"      Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD002876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/82\">",
"      Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/83\">",
"      Taylor-Clark T, Sodha R, Warner B, Foreman J. Histamine receptors that influence blockage of the normal human nasal airway. Br J Pharmacol 2005; 144:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/84\">",
"      Kotaru C, Coreno A, Skowronski M, et al. Exhaled nitric oxide and thermally induced asthma. Am J Respir Crit Care Med 2001; 163:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/85\">",
"      Kanazawa H, Asai K, Hirata K, Yoshikawa J. Vascular involvement in exercise-induced airway narrowing in patients with bronchial asthma. Chest 2002; 122:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/86\">",
"      Dear JW, Scadding GK, Foreman JC. Reduction by NG-nitro-L-arginine methyl ester (L-NAME) of antigen-induced nasal airway plasma extravasation in human subjects in vivo. Br J Pharmacol 1995; 116:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/87\">",
"      Weinfeld D, Ternesten-Hass&eacute;us E, L&ouml;whagen O, Millqvist E. Capsaicin cough sensitivity in allergic asthmatic patients increases during the birch pollen season. Ann Allergy Asthma Immunol 2002; 89:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/88\">",
"      Koskela HO, Purokivi MK, Kontra KM, et al. Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. Clin Exp Allergy 2008; 38:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/89\">",
"      Ollerenshaw SL, Jarvis D, Sullivan CE, Woolcock AJ. Substance P immunoreactive nerves in airways from asthmatics and nonasthmatics. Eur Respir J 1991; 4:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/90\">",
"      Figueroa JM, Mansilla E, Suburo AM. Innervation of nasal turbinate blood vessels in rhinitic and nonrhinitic children. Am J Respir Crit Care Med 1998; 157:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/91\">",
"      Hunter DD, Satterfield BE, Huang J, et al. Toluene diisocyanate enhances substance P in sensory neurons innervating the nasal mucosa. Am J Respir Crit Care Med 2000; 161:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/92\">",
"      Lee SY, Kim MK, Shin C, et al. Substance P-immunoreactive nerves in endobronchial biopsies in cough-variant asthma and classic asthma. Respiration 2003; 70:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/93\">",
"      Groneberg DA, Niimi A, Dinh QT, et al. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med 2004; 170:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/94\">",
"      Fischer A, McGregor GP, Saria A, et al. Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation. J Clin Invest 1996; 98:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/95\">",
"      Undem BJ, Hunter DD, Liu M, et al. Allergen-induced sensory neuroplasticity in airways. Int Arch Allergy Immunol 1999; 118:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/96\">",
"      Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/97\">",
"      Chou DL, Daugherty BL, McKenna EK, et al. Chronic aeroallergen during infancy enhances eotaxin-3 expression in airway epithelium and nerves. Am J Respir Cell Mol Biol 2005; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/98\">",
"      Gosens R, Bos IS, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005; 171:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/99\">",
"      Fryer AD, Stein LH, Nie Z, et al. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest 2006; 116:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/100\">",
"      Matthiesen S, Bahulayan A, Kempkens S, et al. Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am J Respir Cell Mol Biol 2006; 35:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/101\">",
"      Verbout NG, Lorton JK, Jacoby DB, Fryer AD. Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/102\">",
"      Bos IS, Gosens R, Zuidhof AB, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007; 30:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/103\">",
"      Skloot G, Permutt S, Togias A. Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. J Clin Invest 1995; 96:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/104\">",
"      Ricciardolo FL, Di Maria GU, Mistretta A, et al. Impairment of bronchoprotection by nitric oxide in severe asthma. Lancet 1997; 350:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/105\">",
"      Ricciardolo FL, Geppetti P, Mistretta A, et al. Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma. Lancet 1996; 348:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/106\">",
"      Gratziou, C, Rovina, N, Lignos, M, et al. Attenuation of deep inspiration (DI) - induced bronchoprotection (BP) by an NO synthase inhibitor. Am J Respir Crit Care Med 2001; 161:A830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/107\">",
"      Grasemann H, Yandava CN, Storm van's Gravesande K, et al. A neuronal NO synthase (NOS1) gene polymorphism is associated with asthma. Biochem Biophys Res Commun 2000; 272:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/108\">",
"      Wechsler ME, Grasemann H, Deykin A, et al. Exhaled nitric oxide in patients with asthma: association with NOS1 genotype. Am J Respir Crit Care Med 2000; 162:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/109\">",
"      Meurs H, McKay S, Maarsingh H, et al. Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br J Pharmacol 2002; 136:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/110\">",
"      Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003; 111:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/111\">",
"      Maarsingh H, Leusink J, Bos IS, et al. Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma. Respir Res 2006; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/112\">",
"      Que LG, Liu L, Yan Y, et al. Protection from experimental asthma by an endogenous bronchodilator. Science 2005; 308:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/113\">",
"      McAlexander MA, Carr MJ. Peripheral mechanisms I: plasticity of peripheral pathways. Handb Exp Pharmacol 2009; :129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/114\">",
"      Bradding P, Mediwake R, Feather IH, et al. TNF alpha is localized to nasal mucosal mast cells and is released in acute allergic rhinitis. Clin Exp Allergy 1995; 25:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/115\">",
"      Lee LY, Gu Q, Gleich GJ. Effects of human eosinophil granule-derived cationic proteins on C-fiber afferents in the rat lung. J Appl Physiol 2001; 91:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/116\">",
"      Oh SB, Tran PB, Gillard SE, et al. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001; 21:5027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/117\">",
"      van Houwelingen AH, Kool M, de Jager SC, et al. Mast cell-derived TNF-alpha primes sensory nerve endings in a pulmonary hypersensitivity reaction. J Immunol 2002; 168:5297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/118\">",
"      Nassenstein C, Schulte-Herbr&uuml;ggen O, Renz H, Braun A. Nerve growth factor: the central hub in the development of allergic asthma? Eur J Pharmacol 2006; 533:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/119\">",
"      Quarcoo D, Schulte-Herbr&uuml;ggen O, Lommatzsch M, et al. Nerve growth factor induces increased airway inflammation via a neuropeptide-dependent mechanism in a transgenic animal model of allergic airway inflammation. Clin Exp Allergy 2004; 34:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/120\">",
"      Bonini S, Lambiase A, Bonini S, et al. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl Acad Sci U S A 1996; 93:10955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/121\">",
"      Virchow JC, Julius P, Lommatzsch M, et al. Neurotrophins are increased in bronchoalveolar lavage fluid after segmental allergen provocation. Am J Respir Crit Care Med 1998; 158:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/122\">",
"      Sanico AM, Stanisz AM, Gleeson TD, et al. Nerve growth factor expression and release in allergic inflammatory disease of the upper airways. Am J Respir Crit Care Med 2000; 161:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/123\">",
"      Lommatzsch M, Schloetcke K, Klotz J, et al. Brain-derived neurotrophic factor in platelets and airflow limitation in asthma. Am J Respir Crit Care Med 2005; 171:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/124\">",
"      Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/125\">",
"      Kerzel S, P&auml;th G, Nockher WA, et al. Pan-neurotrophin receptor p75 contributes to neuronal hyperreactivity and airway inflammation in a murine model of experimental asthma. Am J Respir Cell Mol Biol 2003; 28:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/126\">",
"      de Vries A, van Rijnsoever C, Engels F, et al. The role of sensory nerve endings in nerve growth factor-induced airway hyperresponsiveness to histamine in guinea-pigs. Br J Pharmacol 2001; 134:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/127\">",
"      Bachar O, Adner M, Uddman R, Cardell LO. Nerve growth factor enhances cholinergic innervation and contractile response to electric field stimulation in a murine in vitro model of chronic asthma. Clin Exp Allergy 2004; 34:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/128\">",
"      Braun A, Lommatzsch M, Neuhaus-Steinmetz U, et al. Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation. Br J Pharmacol 2004; 141:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/129\">",
"      Hoyle GW, Graham RM, Finkelstein JB, et al. Hyperinnervation of the airways in transgenic mice overexpressing nerve growth factor. Am J Respir Cell Mol Biol 1998; 18:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/130\">",
"      Hunter DD, Myers AC, Undem BJ. Nerve growth factor-induced phenotypic switch in guinea pig airway sensory neurons. Am J Respir Crit Care Med 2000; 161:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/131\">",
"      Dinh QT, Groneberg DA, Peiser C, et al. Nerve growth factor-induced substance P in capsaicin-insensitive vagal neurons innervating the lower mouse airway. Clin Exp Allergy 2004; 34:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/132\">",
"      Braun A, Lommatzsch M, Mannsfeldt A, et al. Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 1999; 21:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/133\">",
"      Hahn C, Islamian AP, Renz H, Nockher WA. Airway epithelial cells produce neurotrophins and promote the survival of eosinophils during allergic airway inflammation. J Allergy Clin Immunol 2006; 117:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/134\">",
"      Olgart H&ouml;glund C, de Blay F, Oster JP, et al. Nerve growth factor levels and localisation in human asthmatic bronchi. Eur Respir J 2002; 20:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/135\">",
"      Braman SS. Proceedings from an ACCP International Roundtable Conference. Chest 2006; 130:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/136\">",
"      Mazzone SB, Canning BJ. Synergistic interactions between airway afferent nerve subtypes mediating reflex bronchospasm in guinea pigs. Am J Physiol Regul Integr Comp Physiol 2002; 283:R86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/137\">",
"      Mazzone SB, Mori N, Canning BJ. Synergistic interactions between airway afferent nerve subtypes regulating the cough reflex in guinea-pigs. J Physiol 2005; 569:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/138\">",
"      Harding SM, Richter JE. The role of gastroesophageal reflux in chronic cough and asthma. Chest 1997; 111:1389.",
"     </a>",
"    </li>",
"    <li>",
"     Stein MR. Gastroesophageal Reflux Disease and Airway Disease, Stein MR (Ed), Marcel Dekker, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/140\">",
"      Empey DW, Laitinen LA, Jacobs L, et al. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 1976; 113:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/60/10186/abstract/141\">",
"      Folkerts G, Busse WW, Nijkamp FP, et al. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med 1998; 157:1708.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 529 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10186=[""].join("\n");
var outline_f9_60_10186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7079462\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UPPER AIRWAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Afferent innervation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Efferent innervation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reflex regulation of upper airway function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LOWER AIRWAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extrinsic innervation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vagus nerves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Spinal afferent and sympathetic nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intrinsic innervation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nerve plexuses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Airway parasympathetic ganglia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reflex regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Afferent nerve subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Autonomic nerve subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Autonomic reflexes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7079588\">",
"      AXON REFLEXES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chronic airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Airway hyperresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cough",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7079462\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/529|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/10/2222\" title=\"figure 1\">",
"      Symptoms airway disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7488\" title=\"figure 2\">",
"      Innervation of upper airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/29/15824\" title=\"figure 3\">",
"      Innervation of lower airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/5/9302\" title=\"figure 4\">",
"      Multiple nerve plexuses A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/11/23728\" title=\"figure 5\">",
"      Parasympathetic ganglia neurons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/60/17346\" title=\"figure 6\">",
"      Afferent nerve subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/34/30253\" title=\"figure 7\">",
"      Tiotropium bromide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/529|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/18/44323\" title=\"picture 1\">",
"      Multiple nerve plexuses B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/60/31682\" title=\"picture 2\">",
"      Noncholinergic neurotransmitter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/9/11421\" title=\"table 1\">",
"      Neurotransmitters airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/21/1372\" title=\"table 2\">",
"      Effect of anticholinergics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13801?source=related_link\">",
"      Anatomy and etiology of taste and smell disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=related_link\">",
"      Chronic obstructive pulmonary disease: Risk factors and risk reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=related_link\">",
"      Pathogenesis of allergic rhinitis (rhinosinusitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_60_10187="Fibromyalgia CFS PI";
var content_f9_60_10187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F62764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F62764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical similarities between fibromyalgia and chronic fatigue syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        80 to 90 percent women, usual age 20 to 55 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myalgias and fatigue in more than 90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Associated common symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neurocognitive and mood disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Headaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sleep disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No identifiable cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Testing not helpful",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Physical examination usually normal except for tender points which are required for diagnosis of fibromyalgia and present in most patients with chronic fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal laboratory and radiologic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic symptoms, no highly effective therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10187=[""].join("\n");
var outline_f9_60_10187=null;
var title_f9_60_10188="Axial signs symptoms ALS";
var content_f9_60_10188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Axial signs and symptoms associated with amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Upper motor neuron signs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Absent abdominal reflexes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lower motor neuron signs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neck extension weakness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Truncal extension weakness; bent spine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Abdominal protuberance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased lumbar lordosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Upper motor neuron symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stiffness and imbalance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lower motor neuron symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Neck extensors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Difficulty holding up the head",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            When severe produces head drop",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Truncal extensors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Difficulty maintaining an erect posture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Lumbar extensors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Increased lumbar lordosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Abdominal wall muscles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Abdominal protuberance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cramps",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10188=[""].join("\n");
var outline_f9_60_10188=null;
var title_f9_60_10189="Medications and dyspareunia";
var content_f9_60_10189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications associated with dyspareunia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category or mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific medications or classes of medications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications that may induce vulvovaginal atrophy",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Aromatase inhibitors",
"         </li>",
"         <li>",
"          Gonadotropin-releasing hormone agonists or antagonists",
"         </li>",
"         <li>",
"          Some chemotherapeutic agents",
"         </li>",
"         <li>",
"          Tamoxifen",
"         </li>",
"         <li>",
"          Depot medroxyprogesterone acetate",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         If menopause is induced, vaginal atrophy will result. If the effect is temporary, these changes will reverse when the medication is discontinued.",
"        </p>",
"        <p>",
"         Some chemotherapeutic agents result in premature ovarian failure.",
"        </p>",
"        <p>",
"         In premenopausal women, tamoxifen has an anti-estrogenic effect on the vaginal epithelium, resulting in atrophy.",
"         <sup>",
"          [1]",
"         </sup>",
"         In contrast, in postmenopausal women, tamoxifen has an estrogenic effect on the vaginal epithelium. This results in increased vaginal discharge. Some postmenopausal women who are taking tamoxifen develop recurrent candidal vulvovaginitis, with resultant dyspareunia.",
"        </p>",
"        <p>",
"         Depot medroxyprogesterone acetate suppresses the hypothalamic-pituitary axis, which induces hypoestrogenism and vaginal atrophy.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Some data suggest that oral contraceptives are associated with vestibulodynia. The mechanism of this is unclear.",
"        <sup>",
"         [2]",
"        </sup>",
"        These findings have not been investigated for other formulations of estrogen-progestin contraceptives (patch, vaginal ring).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergics",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Anti-histamines (eg, diphenhydramine, chlorpheniramine)",
"         </li>",
"         <li>",
"          Amitriptyline",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        May result in vaginal dryness and dyspareunia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications that increase the risk of recurrent candidal vulvovaginitis",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Immunosuppressants (eg, glucocorticoids, TNF-alpha inhibitors)",
"         </li>",
"         <li>",
"          Antibiotics",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Candidal vulvovaginitis is associated with the development of vulvodynia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical agents that cause irritant or allergic reactions",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Spermicides",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications that may result in painful clitoral tumescence",
"        <sup>",
"         [3-9]",
"        </sup>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Serotonergic agents (Citalopram, Nefazodone, Trazodone)",
"         </li>",
"         <li>",
"          Dopaminergic agents (Bupropion, Bromocriptine, Olanzapine)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihypertensives",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Sexual dysfunction appears to occur more frequently in hypertensive women. It is unclear whether this is associated with the hypertension itself or with antihypertensive medications.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Mouritz MJ, et al. Obstet Gynecol 2001; 97:855.",
"       </li>",
"       <li>",
"        Goldstein A, et al. J Sex Med 2010; 7:1585.",
"       </li>",
"       <li>",
"        Berk M, et al. Int Clin Psychopharmacol 1997; 12:121.",
"       </li>",
"       <li>",
"        Brodie-Meijer CC, et al. Int Clin Psychopharmacol 1999; 14:257.",
"       </li>",
"       <li>",
"        Battaglia, et al. J Sex Med 2009; 6:2896.",
"       </li>",
"       <li>",
"        Pescatori ES, et al. J Urol 1993; 149:1557.",
"       </li>",
"       <li>",
"        Levenson JL. Am J Psychiatry 1995; 152:813.",
"       </li>",
"       <li>",
"        Blin O, et al. Lancet 1991; 18:1231.",
"       </li>",
"       <li>",
"        Bucur M, et al. J Clin Psychopharmacol 2004; 24:572.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10189=[""].join("\n");
var outline_f9_60_10189=null;
var title_f9_60_10190="Disequilibrium pH";
var content_f9_60_10190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disequilibrium pH and bicarbonate reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 194px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in luminal (tubular fluid) pH and total CO2 concentration as perfusion fluid flows through S2 (mid) and S3 (late) segments of the proximal tubule. The total CO2 concentration is equal to the sum of the concentrations of HCO3- and of dissolved CO2 (equal to 0.03 x PCO2). The S2 segment contains carbonic anhydrase in the lumen; as a result, H+ secretion results in a fall in luminal pH and in total CO2 concentration, since a substantial amount of HCO3- reabsorption has occurred. In comparison, the S3 segment lacks luminal carbonic anhydrase. Consequently, the luminal pH falls to a similar degree, even though there has been a relatively small amount of H+ secretion that is insufficient to lower the total CO2 concentration. This segment also demonstrates a disequilibrium pH as the measured value is 6.89, while the calculated value is 7.35 (similar to that in the initial perfusate). The lack of change in the calculated pH from that in the perfusate is a reflection of the stable total CO2 concentration, whereas the reduction in the measured pH is a reflection of the accumulation of H2CO3. There is no disequilibrium pH in the S2 segment, as the measured and calculated values are the same.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kurtz, I, Star, R, Balaban, RS, et al, J Clin Invest,78:989, 1986, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10190=[""].join("\n");
var outline_f9_60_10190=null;
var title_f9_60_10191="Sigmoid cancer in UC BE";
var content_f9_60_10191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sigmoid cancer developing in ulcerative colitis, as seen on barium enema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium enema study demonstrates a focal stricture in the sigmoid colon caused by an infiltrating cancer. The adjacent bowel is featureless and folds are absent, findings characteristic of chronic ulcerative colitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_60_10191=[""].join("\n");
var outline_f9_60_10191=null;
